Details of the Drug

General Information of Drug (ID: DM5TVS3)

• Drug Name: Vinblastine
• Synonyms: Nincaluicolflastine; Rozevin; VLB; Vinblastin; Vinblastina; Vinblastinum; Vincaleucoblastin; Vincaleucoblastine; Vincaleukoblastine; Vincoblastine; Vinblastina [DCIT]; VR-8; Vinblastina (TN); Vinblastine (INN); Vinblastine [INN:BAN]; Vinblastinum [INN-Latin]; NDC 0002-1452-01; (2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE; (2xi,3beta,4'beta,19xi)-vincaleukoblastine; 1H-Indolizino(8,1-cd)carbazole-5-carboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Advanced cancer	2A00-2F9Z	Approved	[1]
Anterior urethra cancer	N.A.	Approved	[1]
Extragonadal germ cell tumor	N.A.	Approved	[1]
Gestational trophoblastic neoplasia	2F33-2F76	Approved	[1]
Kaposi sarcoma	2B57	Approved	[1]
Mycosis fungoides	2B01	Approved	[1]
Posterior urethra cancer	N.A.	Approved	[1]
Solid tumour/cancer	2A00-2F9Z	Approved	[2]
Testicular cancer	2C80	Approved	[1]
Testicular germ cell tumor	N.A.	Approved	[1]
Classic Hodgkin lymphoma	N.A.	Investigative	[1]

• Therapeutic Class: Anticancer Agents
• Affected Organisms: Humans and other mammals
• ATC Code:
  L01CA01: Vinblastine
  L01CA: Vinca alkaloids and analogues
  L01C: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
  L01: ANTINEOPLASTIC AGENTS
  L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 2:
  Molecular Weight (mw); 811
  Logarithm of the Partition Coefficient (xlogp); 3.7
  Rotatable Bond Count (rotbonds); 10
  Hydrogen Bond Donor Count (hbonddonor); 3
  Hydrogen Bond Acceptor Count (hbondacc); 12
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 3.1 mL/min/kg [4]
  Elimination: 0.5% of drug is excreted from urine in the unchanged form [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 19 hours [4]
  Metabolism: The drug is metabolized via the hepatic []
  Unbound Fraction: The unbound fraction of drug in plasma is 0.14% [4]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 28 L/kg [4]
  Water Solubility: The ability of drug to dissolve in water is measured as 10 mg/mL [3]
• Chemical Identifiers:
  Formula: C46H58N4O9
  IUPAC Name: methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
  Canonical SMILES: CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O
  InChI: InChI=1S/C46H58N4O9/c1-8-42(54)23-28-24-45(40(52)57-6,36-30(15-19-49(25-28)26-42)29-13-10-11-14-33(29)47-36)32-21-31-34(22-35(32)56-5)48(4)38-44(31)17-20-50-18-12-16-43(9-2,37(44)50)39(59-27(3)51)46(38,55)41(53)58-7/h10-14,16,21-22,28,37-39,47,54-55H,8-9,15,17-20,23-26H2,1-7H3/t28-,37-,38+,39+,42-,43+,44+,45-,46-/m0/s1
  InChIKey: JXLYSJRDGCGARV-CFWMRBGOSA-N
• Cross-matching ID:
  PubChem CID: 13342
  CAS Number: 865-21-4
  UNII: 5V9KLZ54CY
  DrugBank ID: DB00570
  TTD ID: D0W9MM
  VARIDT ID: DR00308
  INTEDE ID: DR1689
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tubulin beta-2 chain (TUBB2)	TTJ2PTI	TBB2A_HUMAN	Inhibitor	[5]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance protein 3 (ABCB4)	DTZRMK5	MDR3_HUMAN	Substrate	[6]
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[7]
Multidrug resistance-associated protein 1 (ABCC1)	DTSYQGK	MRP1_HUMAN	Substrate	[8]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[9]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[10]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[11]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[12]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[13]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
14-3-3 protein theta	OTWG7F3H	1433T_HUMAN	Drug Response	[14]
3-oxo-5-alpha-steroid 4-dehydrogenase 1 (SRD5A1)	OTQRET2B	S5A1_HUMAN	Drug Response	[14]
Acetyl-CoA acetyltransferase, cytosolic (ACAT2)	OTZ092ZJ	THIC_HUMAN	Drug Response	[14]
Actin-binding LIM protein 1 (ABLIM1)	OTHXEK3E	ABLM1_HUMAN	Drug Response	[14]
Acyl-coenzyme A thioesterase 13 (ACOT13)	OTWRUST1	ACO13_HUMAN	Drug Response	[14]
Aldehyde oxidase (AOX1)	OT2FZP6H	AOXA_HUMAN	Drug Response	[14]
ATP synthase subunit e, mitochondrial (ATP5ME)	OTADVEE2	ATP5I_HUMAN	Drug Response	[14]
ATP synthase subunit f, mitochondrial (ATP5MF)	OTE4TBG9	ATPK_HUMAN	Drug Response	[14]
ATP-binding cassette sub-family A member 2 (ABCA2)	OTVSYK0X	ABCA2_HUMAN	Drug Response	[15]
ATP-binding cassette sub-family C member 2 (ABCC2)	OTJSIGV5	MRP2_HUMAN	Regulation of Drug Effects	[16]

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 38 Cell Line(s) in Bone Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
RPMI-3460/CS1	GDSC1; GDSC2	-7.0945	-4.5944	-7.1742	38.2157
ES8	GDSC1; GDSC2	-8.679	-7.156	-8.6796	53.7529
EW-1	GDSC1; GDSC2	-8.4056	-6.3404	-8.414	51.0051
ES7	GDSC1; GDSC2	-7.8786	-5.5602	-7.9063	45.804
ES5	GDSC1	-7.7733	-4.8469	-7.8643	55.0994
ES1	GDSC1; GDSC2	-7.7101	-5.2344	-7.755	44.1833
SK-PN-DW	GDSC1; GDSC2	-7.6928	-3.6764	-8.0001	44.6285
MHH-ES-1	GDSC1; GDSC2	-7.5691	-5.864	-7.5756	42.6482
TC-71	GDSC1; GDSC2	-7.4718	-6.5063	-7.4719	41.6447
HOS	GDSC1; GDSC2	-7.3671	-5.9456	-7.3695	40.605
MG-63	GDSC1; GDSC2	-7.1623	-4.5911	-7.2471	38.9089
EW-11	GDSC1; GDSC2	-7.1198	-3.0572	-7.5419	39.7017
EW-16	GDSC1; GDSC2	-6.9603	-4.9342	-6.9953	36.6792
A-673	GDSC1; GDSC2	-6.917	-5.6063	-6.9199	36.0912
CAL-78	GDSC1; GDSC2	-6.6166	-3.9292	-6.7717	33.813
CHSA0108	GDSC1	-6.5293	-1.0498	-7.6265	43.4406
SJSA-1	GDSC1; GDSC2	-6.4974	-4.177	-6.597	32.3604
HuO9	GDSC1; GDSC2	-6.0899	-2.4393	-6.6227	30.4458
NY	GDSC1; GDSC2	-5.9685	-1.1039	-7.0162	31.6316
SK-ES-1	GDSC1; GDSC2	-5.8626	-3.0421	-6.1758	27.1235
EW-3	GDSC1; GDSC2	-5.7105	-2.2874	-6.2696	26.9046
EW-22	GDSC1; GDSC2	-5.6889	-0.0787	-7.1775	31.0209
HuO-3N1	GDSC1; GDSC2	-5.5919	-1.0653	-6.6416	28.2223
ES4	GDSC1; GDSC2	-5.4239	-0.7347	-6.6144	27.3582
U2OS	GDSC1; GDSC2	-5.3356	-1.9036	-6.0211	23.9254
EW-18	GDSC1; GDSC2	-4.92	2.1408	-7.4775	29.0555
EW-7	GDSC1; GDSC2	-4.846	4.1623	-8.3994	31.9308
CAL-72	GDSC1; GDSC2	-4.8348	-0.3687	-6.1924	22.7938
SaOS-2	GDSC1; GDSC2	-4.6933	-0.0254	-6.2171	22.3799
CHSA8926	GDSC1; GDSC2	-4.4677	2.2273	-7.101	25.8337
NOS-1 [Human HNSCC]	GDSC1; GDSC2	-4.4033	-1.1942	-5.3816	16.5338
G-292 clone A141B1	GDSC1; GDSC2	-4.1232	2.861	-7.1042	24.646
CHSA0011	GDSC1	-3.6967	0.7445	-5.6753	19.3894
CADO-ES1	GDSC1; GDSC2	-3.2293	0.8512	-5.3319	12.3765
ES6	GDSC1; GDSC2	-3.22	2.1304	-5.9636	16.0435
EW-24	GDSC1; GDSC2	-2.0656	5.4271	-6.6987	16.7425
EW-13	GDSC1; GDSC2	-2.0245	6.0311	-6.9661	17.8986
H-EMC-SS	GDSC1; GDSC2	-0.9035	6.0206	-6.164	11.443

Cancer Drug Sensitivity Data Curated from 161 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JM1	GDSC1	-6.5274	-4.2016	-6.6252	40.5515
SKM-1	GDSC1	-10.4058	-6.9699	-10.4392	80.1082
SUP-M2	GDSC1; GDSC2	-10.3745	-8.6577	-10.3747	70.5882
CRO-AP2	GDSC1	-10.1132	-5.7043	-10.2448	74.7748
NB4	GDSC1	-9.8993	-9.0891	-9.8993	82.1214
ALL-SIL	GDSC1; GDSC2	-9.8578	-7.346	-9.8653	65.068
ATN-1	GDSC1; GDSC2	-9.7837	-8.1029	-9.784	64.7678
RPMI-8866	GDSC1	-9.6636	-6.5134	-9.6975	74.5831
SR	GDSC1; GDSC2	-9.5784	-7.8344	-9.579	62.7134
JVM-3	GDSC1; GDSC2	-9.564	-7.4324	-9.5671	62.4475
BL-41	GDSC1; GDSC2	-9.4771	-8.4507	-9.4771	61.7665
BE-13	GDSC1; GDSC2	-9.3563	-5.5367	-9.4611	59.3597
Ramos.2G6.4C10	GDSC1; GDSC2	-9.3158	-6.8465	-9.3266	59.8789
EoL-1	GDSC1; GDSC2	-9.1506	-7.4015	-9.1516	58.4524
NKM-1	GDSC1; GDSC2	-9.1384	-6.1954	-9.1728	57.9487
SU-DHL-5	GDSC1; GDSC2	-9.1244	-7.4978	-9.125	58.2048
DEL	GDSC1; GDSC2	-9.1056	-5.8758	-9.162	57.4911
P32/ISH	GDSC1; GDSC2	-9.091	-7.4198	-9.0917	57.8662
U-698-M	GDSC1; GDSC2	-9.0781	-6.7853	-9.0864	57.6215
JeKo-1	GDSC1	-9.0716	-5.4679	-9.1673	67.8441
BV-173	GDSC1; GDSC2	-8.9911	-6.1717	-9.0217	56.6005
SU-DHL-6	GDSC1; GDSC2	-8.9571	-7.345	-8.9578	56.5331
SU-DHL-10	GDSC2	-8.9569	-8.26	-8.9569	56.5479
A4/Fukuda	GDSC1; GDSC2	-8.9419	-6.8296	-8.9474	56.3203
MV4-11	GDSC1; GDSC2	-8.8951	-6.6045	-8.905	55.8234
DB	GDSC1; GDSC2	-8.887	-5.4555	-8.9731	55.3742
MOLT-16	GDSC1; GDSC2	-8.866	-7.9354	-8.866	55.6355
DoHH2	GDSC1	-8.7749	-6.8902	-8.7779	67.6438
MHH-PREB-1	GDSC1; GDSC2	-8.7722	-6.9419	-8.7746	54.6694
JJN-3	GDSC1; GDSC2	-8.7704	-6.5362	-8.7799	54.6041
NU-DUL-1	GDSC1	-8.7285	-7.1871	-8.7291	67.3714
KMS-12-BM	GDSC1; GDSC2	-8.7198	-8.0115	-8.7198	54.1682
CTV-1	GDSC1; GDSC2	-8.5867	-5.4059	-8.661	52.6561
WSU-NHL	GDSC1; GDSC2	-8.5447	-5.6195	-8.5964	52.2991
Karpas-231	GDSC1; GDSC2	-8.4995	-7.1601	-8.4997	51.956
Jurkat	GDSC1; GDSC2	-8.4761	-5.4196	-8.5429	51.6294
NALM-6	GDSC1; GDSC2	-8.4749	-6.8046	-8.4766	51.7055
AMO1	GDSC1; GDSC2	-8.4694	-6.497	-8.4751	51.6421
ALL-PO	GDSC1; GDSC2	-8.325	-3.6198	-8.7035	50.1694
Karpas-45	GDSC1; GDSC2	-8.2521	-5.6724	-8.2868	49.4897
Reh	GDSC1; GDSC2	-8.2281	-6.6914	-8.2294	49.2354
HDLM-2	GDSC1; GDSC2	-8.1856	-5.0456	-8.2776	48.8784
KOPN-8	GDSC1; GDSC2	-8.1663	-5.8209	-8.1889	48.6401
WSU-DLCL2	GDSC1; GDSC2	-8.1448	-6.836	-8.1452	48.399
CCRF-CEM	GDSC1; GDSC2	-8.1333	-5.3395	-8.1898	48.3498
RPMI-8226	GDSC1; GDSC2	-8.098	-5.3262	-8.1539	48.0065
RL	GDSC1	-8.0848	-2.535	-8.7541	56.2611
GR-ST	GDSC1; GDSC2	-8.0204	-2.0909	-8.8316	47.9278
H9	GDSC1; GDSC2	-8.011	-6.3683	-8.0138	47.0625
CTB-1	GDSC1	-7.9612	-3.7541	-8.2737	56.2073
HL-60	GDSC1; GDSC2	-7.9485	-4.7262	-8.0685	46.6614
OCI-Ly7	GDSC1	-7.9294	-6.8354	-7.9295	57.5869
MLMA	GDSC1; GDSC2	-7.9267	-5.0011	-8.008	46.3873
L-540	GDSC1; GDSC2	-7.9262	-3.9872	-8.182	46.6511
JURL-MK1	GDSC1	-7.9075	-2.6399	-8.5279	54.9844
MOLM-13	GDSC1; GDSC2	-7.8804	-6.3742	-7.8821	45.7506
L-363	GDSC1; GDSC2	-7.8572	-4.5937	-7.9912	45.819
MOLM-16	GDSC1	-7.8303	-3.0038	-8.3325	54.5745
SU-DHL-16	GDSC1	-7.8301	-5.8175	-7.8434	56.1853
697	GDSC1; GDSC2	-7.7568	-6.0364	-7.7622	44.5252
CML-T1	GDSC1; GDSC2	-7.7536	-5.2108	-7.8028	44.6244
KE-37	GDSC1; GDSC2	-7.7507	-6.2461	-7.7528	44.4518
NOMO-1	GDSC1; GDSC2	-7.75	-4.8294	-7.8418	44.6989
MOLT-4	GDSC1; GDSC2	-7.7425	-6.2699	-7.7443	44.3684
Namalwa	GDSC1; GDSC2	-7.7397	-6.1581	-7.7428	44.3454
KY821	GDSC1; GDSC2	-7.7173	-5.7425	-7.7308	44.1577
ST486	GDSC1; GDSC2	-7.7034	-5.5128	-7.7277	44.0546
OCI-AML-3	GDSC1; GDSC2	-7.6792	-5.3088	-7.7165	43.8546
TUR	GDSC1; GDSC2	-7.6208	-4.959	-7.6886	43.3717
RCH-ACV	GDSC1	-7.5834	-5.4565	-7.6068	53.164
JSC-1	GDSC1; GDSC2	-7.5833	-3.1357	-8.0247	43.9199
QIMR-WIL	GDSC1	-7.5466	-3.4244	-7.9049	52.2119
OCI-Ly19	GDSC1	-7.5283	-3.5686	-7.8475	52.0728
MOLT-13	GDSC1; GDSC2	-7.5096	-5.59	-7.524	42.0844
A3/Kawakami	GDSC1; GDSC2	-7.5071	-5.6343	-7.5196	42.0516
SCC-3	GDSC2	-7.4678	-6.773	-7.4678	41.604
Hs 445	GDSC2	-7.4498	-4.2395	-7.6136	42.001
SUP-B15	GDSC1; GDSC2	-7.4405	-3.9577	-7.6604	42.0791
RPMI-8402	GDSC1; GDSC2	-7.4187	-5.8681	-7.4229	41.1308
Mono-Mac-6	GDSC1; GDSC2	-7.4006	-2.8035	-7.9247	42.5007
MC116	GDSC1	-7.3934	-6.5756	-7.3935	50.8939
RS4;11	GDSC1; GDSC2	-7.3751	-3.769	-7.6317	41.5691
BALL-1	GDSC1; GDSC2	-7.3091	-2.998	-7.7658	41.5221
SUP-HD1	GDSC1; GDSC2	-7.2852	-2.6971	-7.8326	41.5472
P12-Ichikawa	GDSC1; GDSC2	-7.2685	-5.0786	-7.3058	39.7693
EM-2	GDSC1; GDSC2	-7.2223	-2.9426	-7.6878	40.7655
Karpas-1106P	GDSC1; GDSC2	-7.1959	-1.5429	-8.1407	41.7362
KMS-11	GDSC1	-7.175	-2.2785	-7.8519	48.6871
OCI-AML-5	GDSC1	-7.1705	-5.7089	-7.1745	48.116
Loucy	GDSC1; GDSC2	-7.0416	-6.2369	-7.0417	37.3278
DG-75	GDSC1; GDSC2	-7.0395	-4.9197	-7.0796	37.4948
WIL2 NS	GDSC1; GDSC2	-7.0136	-3.7102	-7.2518	38.0581
Jiyoye	GDSC1; GDSC2	-6.9912	-3.2966	-7.3332	38.2301
VAL	GDSC1; GDSC2	-6.9807	-3.933	-7.1662	37.5311
KM-H2	GDSC1; GDSC2	-6.972	-4.1261	-7.1181	37.2836
KG-1	GDSC1; GDSC2	-6.9436	0.3243	-8.6382	41.3733
PL-21	GDSC1	-6.9397	-3.8869	-7.1315	45.7365
Karpas-620	GDSC1; GDSC2	-6.9219	-3.8696	-7.1158	36.9908
KMOE-2	GDSC1; GDSC2	-6.8378	0.5118	-8.6109	40.7866
GA-10	GDSC1; GDSC2	-6.8284	-3.7892	-7.0319	36.1171
NCI-H929	GDSC1; GDSC2	-6.7844	-2.9832	-7.1983	36.5468
LAMA-84	GDSC1; GDSC2	-6.7658	-2.6013	-7.2992	36.8234
P30/OHK	GDSC1; GDSC2	-6.7416	-3.7481	-6.9467	35.2728
P31/FUJ	GDSC1; GDSC2	-6.7283	-3.913	-6.8963	34.9767
SUP-B8	GDSC1	-6.7086	-1.9682	-7.4593	44.4273
MEG-01	GDSC1; GDSC2	-6.6639	-2.5365	-7.2103	35.9304
MM1.S	GDSC1; GDSC2	-6.6621	-3.1014	-7.0297	35.1969
ML-2	GDSC1; GDSC2	-6.6558	-4.5015	-6.7191	33.7672
Karpas-422	GDSC1; GDSC2	-6.6513	-0.052	-8.1737	38.8677
Karpas-299	GDSC1; GDSC2	-6.574	-1.0792	-7.6617	37.024
U266B1	GDSC1; GDSC2	-6.5709	-3.3492	-6.8602	33.9767
SUP-T1	GDSC1; GDSC2	-6.385	0.3427	-8.073	37.2938
EJM	GDSC1; GDSC2	-6.3784	-2.5216	-6.906	33.1766
Kasumi-1	GDSC1	-6.3719	-0.2716	-7.7902	42.7152
KCL-22	GDSC1; GDSC2	-6.3617	-4.5381	-6.4032	30.7133
Sc-1	GDSC1	-6.3593	-5.2945	-6.3612	37.9786
RPMI-6666	GDSC1; GDSC2	-6.3492	-3.1972	-6.6605	31.9117
HH [Human lymphoma]	GDSC1; GDSC2	-6.3339	-0.7729	-7.5367	35.3926
LC4-1	GDSC1; GDSC2	-6.2397	-1.5527	-7.1179	33.3644
Ku812	GDSC1; GDSC2	-6.0215	-2.0937	-6.6755	30.3652
OCI-M1	GDSC1; GDSC2	-6.0194	-3.3306	-6.2634	28.3223
HC-1	GDSC1; GDSC2	-5.9576	-2.5506	-6.4406	28.9238
Granta-519	GDSC1; GDSC2	-5.9369	-1.1121	-6.9798	31.3279
MHH-CALL-2	GDSC1; GDSC2	-5.8774	-1.8252	-6.6255	29.4462
TK [Human B-cell lymphoma]	GDSC1; GDSC2	-5.822	-3.0875	-6.1178	26.6293
MY-M12	GDSC1	-5.6977	-2.0102	-6.3619	33.5336
DND-41	GDSC1; GDSC2	-5.682	-0.3871	-7.0321	30.3852
HT	GDSC1	-5.6762	-1.8471	-6.4036	33.6087
SU-DHL-8	GDSC2	-5.5407	-3.054	-5.8215	23.7499
Farage	GDSC1	-5.5352	-1.0921	-6.5715	33.5581
MOLP-8	GDSC1; GDSC2	-5.4244	-0.7405	-6.6123	27.3502
VL51	GDSC1; GDSC2	-5.3879	0.4358	-7.1131	29.4554
OCI-AML-2	GDSC1; GDSC2	-5.3165	-2.5539	-5.7479	22.3432
IM-9	GDSC1; GDSC2	-5.2884	-3.2041	-5.5013	20.8596
Raji	GDSC1; GDSC2	-5.2784	-2.0063	-5.9191	23.1222
OPM-2	GDSC1; GDSC2	-5.0344	-1.142	-6.0365	22.747
BC-1	GDSC1; GDSC2	-5.0215	-3.1663	-5.2214	18.1169
HEL	GDSC1	-5.0171	-2.5369	-5.433	23.9744
THP-1	GDSC1	-4.7658	-1.9102	-5.4233	22.5672
PF-382	GDSC1; GDSC2	-4.7285	-1.2089	-5.6976	19.6252
K-562	GDSC1; GDSC2	-4.727	2.1177	-7.2861	27.5652
HAL-01	GDSC1; GDSC2	-4.5534	4.4255	-8.2644	30.4939
CA46	GDSC1; GDSC2	-4.4827	0.076	-6.0641	20.7631
ARH-77	GDSC1; GDSC2	-4.4037	-2.469	-4.8095	13.1238
EHEB	GDSC1	-4.3139	1.0611	-6.3866	26.3243
L-428	GDSC1; GDSC2	-4.0693	-0.0132	-5.634	16.8421
MN-60	GDSC1; GDSC2	-4.0607	1.0002	-6.1259	19.6073
CESS	GDSC1; GDSC2	-3.7551	-0.9397	-4.8908	11.2616
YT	GDSC1; GDSC2	-3.6743	3.3739	-6.9678	22.56
SU-DHL-4	GDSC1	-3.4515	-0.4642	-4.8602	12.5572
JVM-2	GDSC1; GDSC2	-3.3263	4.1981	-7.0856	22.0168
Daudi	GDSC1; GDSC2	-3.2502	1.3658	-5.6063	14.0796
L-1236	GDSC1; GDSC2	-3.2312	1.662	-5.7387	14.7968
EB2	GDSC1; GDSC2	-3.1726	-0.3755	-4.6727	8.1233
RC-K8	GDSC1; GDSC2	-3.158	2.7835	-6.2391	17.3657
GDM-1	GDSC1; GDSC2	-3.1206	-0.7009	-4.4687	6.6949
ME1	GDSC1; GDSC2	-2.6671	3.5293	-6.2183	15.8732
CMK	GDSC1	-2.4106	3.6917	-6.1013	17.4575
LP-1	GDSC1	-2.1159	3.7711	-5.9204	15.4563
ROS-50	GDSC1	-0.1295	5.88	-5.6133	8.6973
SK-MM-2	GDSC1; GDSC2	0.1973	2.7471	-4.1539	0.5479

Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Aero Dig Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
OACP4 C	GDSC1; GDSC2	-7.644	-6.2084	-7.6458	43.3805
FLO-1	GDSC1; GDSC2	-7.4476	-4.9532	-7.506	41.6317
KYSE-220	GDSC1; GDSC2	-7.1488	-2.3539	-7.7977	40.623
ESO-26	GDSC1; GDSC2	-6.5139	-4.1404	-6.6209	32.5612
SK-GT-4	GDSC1; GDSC2	-6.5138	-1.401	-7.4687	36.0722
HCE-4	GDSC1	-6.3286	-0.9385	-7.4618	41.712
ESO-51	GDSC1; GDSC2	-5.7157	-1.3409	-6.6528	28.8309
KYSE-50	GDSC1; GDSC2	-4.2165	1.0376	-6.2858	21.0046
OACM5.1 C	GDSC1; GDSC2	-2.6886	4.5896	-6.7631	18.6859
KYAE-1	GDSC1; GDSC2	-1.6964	5.7142	-6.5673	15.2052
TE-12	GDSC1	-0.9667	9.3162	-7.8019	21.5876

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
COLO 684	GDSC1; GDSC2	-5.7051	-1.5159	-6.5688	28.38

Cancer Drug Sensitivity Data Curated from 31 Cell Line(s) in Autonomic Ganglia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
CHP-134	GDSC2	-8.6733	-7.5982	-8.6733	53.7011
SJNB-13	GDSC1; GDSC2	-8.1904	-4.9201	-8.2993	48.933
CHP-212	GDSC1; GDSC2	-7.9198	-4.0551	-8.1603	46.5724
SK-N-MC-IXC	GDSC1	-7.8935	-6.9539	-7.8935	57.1432
SJNB-14	GDSC1; GDSC2	-7.5998	-5.0714	-7.6544	43.1243
NB69	GDSC1; GDSC2	-7.454	-4.6031	-7.5572	41.8496
NB1	GDSC1; GDSC2	-7.3848	-3.1232	-7.8117	42.1246
SK-N-AS	GDSC1; GDSC2	-6.5581	-1.315	-7.5499	36.5783
SK-N-BE(2)-M17	GDSC1; GDSC2	-6.3113	-2.7681	-6.7508	32.141
GI-ME-N	GDSC1; GDSC2	-6.3042	1.3855	-8.4629	37.9252
GOTO	GDSC1; GDSC2	-6.171	-0.3472	-7.5503	34.6461
SJNB-10	GDSC1; GDSC2	-6.0462	-2.199	-6.6626	30.423
SJNB-5	GDSC1	-5.9809	-2.0472	-6.6497	36.7004
Kelly	GDSC1; GDSC2	-5.9805	-3.1026	-6.286	28.2516
SJNB-17	GDSC1	-5.7221	-2.5409	-6.1896	32.7847
KP-N-YS	GDSC1	-5.7081	-0.4763	-7.019	36.4426
IMR-5	GDSC1; GDSC2	-5.3865	-0.5692	-6.6506	27.3715
NH-12	GDSC1; GDSC2	-5.2087	0.1286	-6.793	27.2961
CHP-126	GDSC1	-5.1683	-2.209	-5.7213	26.7143
TGW	GDSC1; GDSC2	-5.1505	-3.0514	-5.3974	19.6669
MHH-NB-11	GDSC1	-4.6406	-1.1251	-5.6482	23.4514
LA-N-6	GDSC1	-4.4633	-0.3126	-5.8586	23.9454
SJNB-6	GDSC1	-3.8347	2.1275	-6.4849	24.7836
SJNB-7	GDSC1; GDSC2	-3.6375	-0.2933	-5.1066	12.2247
SJNB-12	GDSC1; GDSC2	-3.6281	2.9272	-6.7051	21.1745
SK-N-FI	GDSC1; GDSC2	-3.4113	-1.6794	-4.2188	5.9436
SiMa	GDSC1; GDSC2	-3.3998	-0.943	-4.5769	8.1735
KP-N-YN	GDSC1; GDSC2	-3.2863	2.7079	-6.3072	18.1061
SK-N-SH	GDSC1; GDSC2	-3.2534	3.7351	-6.7935	20.4486
SK-N-DZ	GDSC1; GDSC2	-3.151	8.9152	-9.2986	29.2674
NB(TU)1	GDSC1; GDSC2	-1.0063	10.4188	-8.3709	21.1327

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Biliary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HuCC-T1	GDSC1; GDSC2	-5.914	0.7871	-7.7983	34.2906

Cancer Drug Sensitivity Data Curated from 50 Cell Line(s) in Breast Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MDA-MB-361	GDSC1; GDSC2	-9.1573	-6.2544	-9.1888	58.1478
HCC1806	GDSC1; GDSC2	-8.983	-6.1689	-9.0135	56.5245
CAL-148	GDSC2	-8.6636	-4.1509	-8.9478	53.0162
JIMT-1	GDSC1; GDSC2	-7.7772	-5.8241	-7.789	44.7506
CAMA-1	GDSC1; GDSC2	-7.5608	-5.8728	-7.5669	42.5639
EFM-19	GDSC1; GDSC2	-7.5156	-5.2053	-7.5539	42.2342
AU565	GDSC1; GDSC2	-7.3088	-3.2202	-7.7011	41.3435
Hs 578T	GDSC1; GDSC2	-7.1553	-3.9972	-7.3423	39.2361
HCC1187	GDSC1; GDSC2	-7.1509	-4.8924	-7.1993	38.6432
CAL-51	GDSC1; GDSC2	-6.7384	-4.7997	-6.7744	34.4616
HCC38	GDSC1; GDSC2	-6.1896	-3.8134	-6.3323	29.5017
CAL-120	GDSC1; GDSC2	-6.1615	-0.5947	-7.4334	34.1868
MFM-223	GDSC1; GDSC2	-6.1424	-3.6344	-6.3206	29.2108
HCC1395	GDSC1; GDSC2	-6.0525	-0.7197	-7.2668	33.0428
MDA-MB-415	GDSC1; GDSC2	-5.9287	-2.4628	-6.4403	28.7852
OCUB-M	GDSC1; GDSC2	-5.9193	-2.7532	-6.33	28.1852
MDA-MB-468	GDSC1; GDSC2	-5.9142	-1.3236	-6.8677	30.7327
HCC2157	GDSC1; GDSC2	-5.3726	-3.1862	-5.5984	21.7724
T-47D	GDSC1; GDSC2	-5.332	-1.3814	-6.2367	25.0606
HCC1143	GDSC1; GDSC2	-5.091	-0.2908	-6.4816	25.3132
MDA-MB-231	GDSC1; GDSC2	-4.9299	-0.0583	-6.4314	24.4143
BT-20	GDSC1; GDSC2	-4.8604	-0.4883	-6.1616	22.7293
MDA-MB-453	GDSC1; GDSC2	-4.8539	0.0846	-6.4248	24.0821
CAL-85-1	GDSC1; GDSC2	-4.8205	-1.0246	-5.874	20.9892
BT-549	GDSC1; GDSC2	-4.6328	-0.7757	-5.8032	19.8616
MDA-MB-436	GDSC1; GDSC2	-4.5836	-1.2083	-5.5531	18.2276
Evsa-T	GDSC1; GDSC2	-4.453	-0.7536	-5.6381	18.2336
HCC70	GDSC1; GDSC2	-4.2764	5.5058	-8.5544	30.4682
HDQ-P1	GDSC1; GDSC2	-4.2042	0.9255	-6.2193	20.6078
MCF-7	GDSC1; GDSC2	-4.0983	0.2781	-5.8038	17.9295
DU4475	GDSC1; GDSC2	-3.9118	-0.4437	-5.278	14.1718
MRK-nu-1	GDSC1; GDSC2	-3.6456	0.3186	-5.4185	14.1603
HCC1569	GDSC1	-3.3756	3.8482	-6.9519	25.3119
COLO 824	GDSC1; GDSC2	-3.2576	1.6878	-5.7734	15.075
UACC-893	GDSC1	-3.2367	6.5154	-8.1698	29.6075
BT-474	GDSC1; GDSC2	-3.0434	3.6884	-6.5978	18.878
MDA-MB-157	GDSC1; GDSC2	-2.4539	5.7229	-7.1429	19.8047
HCC1954	GDSC1; GDSC2	-2.411	11.4267	-9.9515	29.057
ZR-75-30	GDSC1; GDSC2	-1.7476	1.9135	-4.7728	5.4749
MDA-MB-175-VII	GDSC1; GDSC2	-1.5736	7.3294	-7.2701	18.1536
HCC1428	GDSC1; GDSC2	-1.3975	9.6519	-8.2832	21.7069
EFM-192A	GDSC1; GDSC2	-0.8809	4.4678	-5.4192	7.4851
MDA-MB-330	GDSC1	-0.8422	11.5134	-8.7881	24.783
UACC-812	GDSC2	-0.5142	8.051	-6.8729	14.0613
HCC202	GDSC1	-0.4409	4.7744	-5.2959	7.416
HCC1937	GDSC1; GDSC2	-0.2751	6.2596	-5.8744	8.7815
HCC1419	GDSC1; GDSC2	-0.2236	12.8909	-9.0137	21.6037
HCC2218	GDSC1	-0.08	15.8027	-10.3354	27.3123
HCC1500	GDSC1; GDSC2	0.0396	11.4139	-8.1114	18.0177
BT-483	GDSC1; GDSC2	0.7024	10.4587	-7.2167	13.2517

Cancer Drug Sensitivity Data Curated from 54 Cell Line(s) in Central Nervous System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MOG-G-UVW	GDSC1; GDSC2	-9.8176	-7.8253	-9.819	64.9959
D-566MG	GDSC1	-9.0565	-4.9908	-9.2163	66.7414
Becker	GDSC1; GDSC2	-8.7501	-3.9844	-9.079	53.6512
SF539	GDSC1; GDSC2	-8.6823	-7.0049	-8.6837	53.7803
YH-13	GDSC1; GDSC2	-8.055	-6.3292	-8.0588	47.5057
Daoy	GDSC1; GDSC2	-8.0087	-6.0151	-8.019	47.057
MOG-G-CCM	GDSC1; GDSC2	-7.9896	-5.0142	-8.0732	46.9976
GI-1	GDSC1; GDSC2	-7.7669	-4.9365	-7.8461	44.8326
ONS-76	GDSC1; GDSC2	-7.6396	-1.76	-8.5369	45.1346
PFSK-1	GDSC1; GDSC2	-7.5932	-3.6001	-7.9104	43.7455
H4	GDSC1; GDSC2	-7.454	-5.5198	-7.47	41.5346
U-251MG	GDSC1; GDSC2	-7.2627	-4.8376	-7.3231	39.806
YKG-1	GDSC1	-7.2281	-5.1207	-7.2603	48.8634
D-336MG	GDSC1	-7.2023	-4.298	-7.3357	48.6426
SK-MG-1	GDSC1; GDSC2	-7.1315	-2.9263	-7.5939	39.9342
8-MG-BA	GDSC1; GDSC2	-7.0944	-2.6215	-7.6496	39.8794
A-172	GDSC1; GDSC2	-7.0903	-3.9591	-7.2797	38.6141
GaMG	GDSC1; GDSC2	-7.022	-6.183	-7.022	37.1306
D-247MG	GDSC1	-6.9421	-3.458	-7.2364	45.9625
42-MG-BA	GDSC1; GDSC2	-6.8439	-2.8259	-7.3116	37.3062
D283 Med	GDSC1; GDSC2	-6.8297	-3.8194	-7.0266	36.1016
NMC-G1	GDSC1	-6.7809	-0.6593	-8.0516	45.8448
KALS-1	GDSC1; GDSC2	-6.7117	-2.0577	-7.4299	36.9913
D-423MG	GDSC1	-6.7046	-2.8301	-7.1587	43.7523
SF268	GDSC1; GDSC2	-6.6295	-2.3127	-7.25	35.8956
KS-1 [Human Krukenberg tumour]	GDSC1; GDSC2	-6.4512	-2.6961	-6.9263	33.6403
SNB-75	GDSC1	-6.4346	-0.687	-7.6779	42.8999
T98G	GDSC1; GDSC2	-6.316	-3.5248	-6.5364	31.1467
D-263MG	GDSC1; GDSC2	-6.2218	-1.6124	-7.0752	33.1018
LNZTA3WT4	GDSC1	-6.1407	-3.5517	-6.3386	36.3434
KNS-81-FD	GDSC1	-6.1021	2.2659	-8.6723	42.7033
KINGS-1	GDSC1; GDSC2	-6.1018	-1.5414	-6.9763	32.0997
Hs 683	GDSC1	-6.093	-2.9613	-6.4518	36.5728
LN-229	GDSC1; GDSC2	-6.063	-2.3865	-6.6124	30.2663
M059J	GDSC1; GDSC2	-6.0307	-2.6356	-6.4904	29.5195
DBTRG-05MG	GDSC1; GDSC2	-5.9891	-1.4349	-6.9006	31.2314
SF126	GDSC1	-5.6481	-3.0034	-5.9542	30.9775
KNS-42	GDSC1	-5.5293	-2.9341	-5.847	29.6015
DK-MG	GDSC1; GDSC2	-5.4545	-0.4589	-6.7692	28.221
SW1088	GDSC1; GDSC2	-5.3997	1.2323	-7.499	31.0372
D-502MG	GDSC1	-5.3974	-0.1612	-6.8468	33.9775
D-392MG	GDSC1; GDSC2	-5.321	-0.0641	-6.8151	27.8644
LN-405	GDSC1; GDSC2	-5.0987	1.2229	-7.2038	28.653
AM-38	GDSC1; GDSC2	-5.0339	-0.9023	-6.1441	23.3279
U-87MG ATCC	GDSC1; GDSC2	-4.9002	0.971	-6.8928	26.5209
LN-18	GDSC1; GDSC2	-4.8408	-2.0511	-5.4411	18.5906
SF295	GDSC1	-4.8225	-1.3071	-5.7476	25.0225
D-542MG	GDSC1	-4.7815	-2.1125	-5.3535	22.1671
Onda 11	GDSC1	-4.5207	5.3667	-8.7017	35.766
GB-1	GDSC1; GDSC2	-4.4215	4.5774	-8.2216	29.9083
SW1783	GDSC1; GDSC2	-3.6661	1.3552	-5.9532	17.3498
U-118MG	GDSC1; GDSC2	-3.3324	9.0641	-9.5236	30.3447
CAS-1	GDSC1; GDSC2	-2.7776	3.6957	-6.3881	17.0643
Onda 10	GDSC1	-1.507	6.0601	-6.5999	17.5524

Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
ETK-1	GDSC1; GDSC2	-7.2025	-2.2555	-7.8895	41.185
TGBC24TKB	GDSC1; GDSC2	-5.073	0.1427	-6.6661	26.1456
TGBC1TKB	GDSC1; GDSC2	-4.0958	1.5184	-6.4138	21.2553

Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Endometrium Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
ESS-1	GDSC1; GDSC2	-8.2272	-6.2753	-8.2342	49.2301
MFE-319	GDSC1; GDSC2	-7.3458	-6.1362	-7.3466	40.3838
RL95-2	GDSC1; GDSC2	-6.6559	-5.0193	-6.6727	33.5404
AN3-CA	GDSC1; GDSC2	-6.3248	-2.4775	-6.8631	32.715
MFE-296	GDSC1; GDSC2	-5.1582	-1.1143	-6.1749	24.0025
EN	GDSC1; GDSC2	-4.0863	8.002	-9.6329	32.7348
MFE-280	GDSC1; GDSC2	-3.5744	-0.0399	-5.1778	12.4673
KLE	GDSC1; GDSC2	-1.6009	4.935	-6.1189	12.706

Cancer Drug Sensitivity Data Curated from 33 Cell Line(s) in Kidney Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
RXF 393L	GDSC1	-9.0181	-2.1994	-9.8774	61.8413
SW13	GDSC1; GDSC2	-7.3953	-5.08	-7.4385	41.0564
A-498	GDSC1; GDSC2	-7.1099	-4.9694	-7.149	38.1938
BFTC-909	GDSC1; GDSC2	-7.0654	-4.1907	-7.2071	38.1836
KTCTL-140	GDSC1	-6.9114	-4.2244	-7.0349	45.25
786-O	GDSC1; GDSC2	-6.686	-3.3351	-6.9896	35.1574
LB2241-RCC	GDSC1	-6.4608	-0.794	-7.6604	43.0395
KMRC-20	GDSC1; GDSC2	-6.2616	-1.3723	-7.2133	33.851
KTCTL-195	GDSC1; GDSC2	-6.2367	-3.1309	-6.557	30.8517
UO-31	GDSC1	-6.2136	-2.7022	-6.6663	38.3744
BB65-RCC	GDSC1	-5.6169	-3.1216	-5.8839	30.361
SN12C	GDSC1; GDSC2	-5.4858	-3.3444	-5.6773	22.7196
KTCTL-1M	GDSC1	-5.4359	-0.8994	-6.5537	32.8951
769-P	GDSC1; GDSC2	-5.2884	-2.8276	-5.6208	21.5164
Caki-1	GDSC1	-5.213	-2.262	-5.7479	27.1353
VMRC-RCZ	GDSC1; GDSC2	-5.1618	-0.0679	-6.6552	26.4541
LB1047-RCC	GDSC1	-4.4929	-1.1174	-5.5056	21.7668
TK-10	GDSC1; GDSC2	-4.4107	0.1706	-6.0418	20.3769
LB996-RCC	GDSC2	-4.3682	1.9249	-6.8613	24.3997
CAL-54	GDSC1; GDSC2	-4.1024	-1.5503	-4.9199	12.6371
HA7-RCC	GDSC1	-4.0847	1.0169	-6.1557	24.0165
ACHN	GDSC1; GDSC2	-4.0053	3.1579	-7.1476	24.4399
NCC010	GDSC1	-3.8309	-2.4325	-4.2391	9.3153
KTCTL-13	GDSC1	-3.8034	-0.1174	-5.3413	17.5238
KTCTL-26A	GDSC1	-3.5744	4.9375	-7.6639	29.0216
SW156	GDSC1	-3.5169	-1.0387	-4.6299	11.03
VMRC-RCW	GDSC1	-3.5079	-1.9459	-4.1704	7.3971
NCC021	GDSC1	-3.2415	0.0764	-4.9546	12.4987
KMRC-1	GDSC1; GDSC2	-3.0983	0.6715	-5.1354	10.8031
A-704	GDSC1; GDSC2	-2.9803	3.0116	-6.2087	16.69
RCC10RGB	GDSC1; GDSC2	-2.5832	-0.1898	-4.3233	4.4864
KTCTL-21	GDSC1	-2.4426	1.898	-5.2402	11.9528
OS-RC-2	GDSC1; GDSC2	-0.7555	6.8944	-6.482	12.7187

Cancer Drug Sensitivity Data Curated from 46 Cell Line(s) in Large Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SNU-175	GDSC2	-8.7587	-7.4021	-8.7589	54.5555
GP5d	GDSC1; GDSC2	-7.7447	-5.5557	-7.7679	44.4618
SW48	GDSC1; GDSC2	-7.5642	-5.0454	-7.6194	42.7741
RKO	GDSC1; GDSC2	-7.4954	-5.8345	-7.5014	41.9079
HCT 116	GDSC1; GDSC2	-7.4673	-3.7219	-7.7433	42.4863
MDST8	GDSC1; GDSC2	-7.3942	-4.4094	-7.5235	41.3528
HCC2998	GDSC1; GDSC2	-7.3594	-3.0054	-7.8185	41.9785
KM12	GDSC1; GDSC2	-7.2542	-2.8359	-7.7553	41.151
LoVo	GDSC1; GDSC2	-7.1263	-2.5916	-7.6939	40.1995
SW620	GDSC1; GDSC2	-6.8405	-4.6091	-6.9021	35.6054
COLO205	GDSC1; GDSC2	-6.4579	-2.0711	-7.1521	34.6099
SNU-C5	GDSC1; GDSC2	-6.332	-2.8446	-6.7487	32.236
DiFi	GDSC1; GDSC2	-6.2264	-3.7901	-6.3772	29.9102
HT-29	GDSC1; GDSC2	-5.6983	-2.0363	-6.3524	27.2736
SK-CO-1	GDSC1; GDSC2	-5.5441	-0.9812	-6.6288	27.9502
SNU-C2B	GDSC1; GDSC2	-5.4389	-0.6456	-6.6695	27.6863
SNU-407	GDSC1; GDSC2	-5.3599	-2.7907	-5.7109	22.3306
LS411N	GDSC1; GDSC2	-4.8605	1.9976	-7.3521	28.335
CaR-1	GDSC1; GDSC2	-4.7718	-1.9155	-5.4272	18.23
SW626	GDSC1; GDSC2	-4.6275	-0.0628	-6.1358	21.6935
LS513	GDSC1	-4.4303	-1.5301	-5.252	19.6879
C2BBe1	GDSC1; GDSC2	-3.9271	-1.2845	-4.8804	11.7756
COLO 320HSR	GDSC1; GDSC2	-3.8603	2.7697	-6.8273	22.5071
HCT 15	GDSC1; GDSC2	-3.8467	-2.5861	-4.1844	7.2061
NCI-H716	GDSC1; GDSC2	-3.7229	10.4738	-10.5567	33.6908
SW1463	GDSC1; GDSC2	-3.5839	4.1423	-7.2745	23.6312
SNU-81	GDSC1	-3.5747	1.1165	-5.7552	19.426
CCK-81	GDSC1; GDSC2	-3.5643	-1.9186	-4.2346	6.524
LS180	GDSC1; GDSC2	-3.5371	3.3794	-6.8535	21.5981
CW-2	GDSC1; GDSC2	-3.4225	3.4623	-6.7983	20.9826
LS123	GDSC1; GDSC2	-3.3338	2.2472	-6.1164	17.2258
HT115	GDSC1	-3.2705	-1.6766	-4.1021	5.969
SW837	GDSC1; GDSC2	-2.9161	1.4018	-5.3547	11.6372
CL-11	GDSC1; GDSC2	-2.553	0.0975	-4.441	5.1356
HT-55	GDSC1; GDSC2	-2.545	1.3737	-5.0579	8.8851
SNU-61	GDSC1; GDSC2	-2.2169	3.5531	-5.8876	12.9143
NCI-H508	GDSC1	-2.0306	8.8285	-8.3574	26.5027
NCI-H747	GDSC1; GDSC2	-1.997	3.1917	-5.5515	10.5005
SW948	GDSC1; GDSC2	-1.9961	12.5563	-10.185	28.6459
SNU-C1	GDSC1; GDSC2	-1.3915	5.2706	-6.1352	12.3247
SW1417	GDSC1; GDSC2	-0.8448	3.8989	-5.1365	5.9055
T84	GDSC1; GDSC2	-0.6717	2.8335	-4.5724	2.7775
SW1116	GDSC1; GDSC2	-0.661	4.1709	-5.1518	5.6884
LS1034	GDSC1; GDSC2	0.1161	5.3918	-5.2571	5.0705
RCM-1 [Human ESC]	GDSC1; GDSC2	0.4699	5.8856	-5.2818	4.7183
COLO 678	GDSC1; GDSC2	0.59	7.5319	-5.9395	7.6811

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MO-T	GDSC1; GDSC2	-3.9661	5.3353	-8.1984	28.3443

Cancer Drug Sensitivity Data Curated from 15 Cell Line(s) in Liver Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HLE	GDSC1; GDSC2	-6.9632	-3.2312	-7.3208	38.0223
SNU-387	GDSC1; GDSC2	-6.8809	-3.3224	-7.2058	37.1178
SNU-398	GDSC1; GDSC2	-6.835	-5.1843	-6.8488	35.3222
Hep 3B2.1-7	GDSC1	-6.5988	-2.8123	-7.0492	42.6122
JHH-6	GDSC1; GDSC2	-6.1111	-0.2027	-7.5519	34.3666
JHH-1	GDSC1; GDSC2	-6.0153	-3.2924	-6.2694	28.3332
SNU-423	GDSC1; GDSC2	-5.861	-0.5054	-7.1626	31.7369
SK-HEP-1	GDSC1; GDSC2	-5.5716	-3.2553	-5.7956	23.7521
JHH-7	GDSC1; GDSC2	-5.5019	-1.1888	-6.4953	27.1145
HuH-1	GDSC1; GDSC2	-4.674	-0.9189	-5.777	19.8695
JHH-4	GDSC1; GDSC2	-3.4153	-1.853	-4.1356	5.4299
Huh-7	GDSC1; GDSC2	-3.2534	2.1964	-6.0242	16.4795
JHH-2	GDSC1; GDSC2	-3.2495	2.3329	-6.0892	16.8256
SNU-449	GDSC1; GDSC2	-2.9288	0.2595	-4.7965	8.2427
Hep-G2/C3A	GDSC1; GDSC2	-2.1854	3.2726	-5.7267	11.9388

Cancer Drug Sensitivity Data Curated from 179 Cell Line(s) in Lung Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
NCI-H1703	GDSC1; GDSC2	-9.1308	-7.4169	-9.1317	58.2592
IST-SL1	GDSC1	-9.0848	0.6914	-11.0281	59.1891
NCI-H446	GDSC1; GDSC2	-8.9077	-2.7396	-9.5862	54.2905
NCI-H2122	GDSC1; GDSC2	-8.8204	-5.0931	-8.9482	54.6496
NCI-H1792	GDSC1; GDSC2	-8.759	-7.7571	-8.759	54.5614
HCC44	GDSC1; GDSC2	-8.4182	-5.9543	-8.4418	51.115
A-427	GDSC1	-8.2981	-5.3995	-8.3575	60.99
NCI-H524	GDSC1; GDSC2	-8.2445	-4.3806	-8.4465	49.4658
EMC-BAC-2	GDSC1; GDSC2	-8.2051	-4.8584	-8.3238	49.076
PC-14	GDSC1; GDSC2	-7.9454	-5.6567	-7.9698	46.4583
NCI-H841	GDSC1; GDSC2	-7.9431	-5.8326	-7.9586	46.4155
HARA [Human squamous cell lung carcinoma]	GDSC1; GDSC2	-7.9429	-5.7637	-7.9615	46.4199
NCI-H3122	GDSC1; GDSC2	-7.9115	-1.5503	-8.9058	47.2559
EMC-BAC-1	GDSC1	-7.8829	-3.6362	-8.2173	55.4252
NCI-H2369	GDSC1; GDSC2	-7.8514	-5.3201	-7.8957	45.5757
VMRC-LCD	GDSC1; GDSC2	-7.7708	-5.4913	-7.7989	44.7358
NCI-H292	GDSC1	-7.7387	-3.2715	-8.1559	53.9255
NCI-H1581	GDSC1; GDSC2	-7.6742	-4.5176	-7.8067	44.0686
LK-2	GDSC1; GDSC2	-7.6098	-6.2501	-7.611	43.0345
NCI-H1648	GDSC1; GDSC2	-7.527	-3.7118	-7.8108	43.0596
HCC15	GDSC1; GDSC2	-7.5248	-5.0701	-7.5756	42.3695
NCI-H510A	GDSC1	-7.4791	-4.1494	-7.6626	51.7021
NCI-H23	GDSC1; GDSC2	-7.4684	-5.3109	-7.4968	41.7272
NCI-H1048	GDSC1; GDSC2	-7.4521	-6.5263	-7.4521	41.4467
NCI-H211	GDSC1; GDSC2	-7.4306	-4.8971	-7.4942	41.4827
DMS 273	GDSC1; GDSC2	-7.3989	-4.4523	-7.5214	41.3759
LCLC-97TM1	GDSC1; GDSC2	-7.3742	-4.4167	-7.5007	41.1484
LC-1/sq	GDSC1; GDSC2	-7.3259	-3.1761	-7.7323	41.5386
SBC-5	GDSC1; GDSC2	-7.2896	-6.2667	-7.2897	39.8164
LOU-NH91	GDSC1; GDSC2	-7.2697	-5.2873	-7.2922	39.7183
A-549	GDSC1; GDSC2	-7.1913	-3.5555	-7.4832	39.9467
NCI-H526	GDSC1; GDSC2	-7.1726	-3.8609	-7.3903	39.5142
NCI-H1437	GDSC1	-7.1673	-5.6777	-7.1719	48.0777
SBC-3	GDSC1; GDSC2	-7.1343	-4.7813	-7.1935	38.5245
NCI-H290	GDSC1	-7.0235	-2.8801	-7.4903	47.0706
LCLC-103H	GDSC1; GDSC2	-7.0222	-3.1161	-7.4182	38.7115
COR-L23	GDSC1; GDSC2	-6.9639	-3.3983	-7.2759	37.8606
CPC-N	GDSC1; GDSC2	-6.9362	-2.494	-7.5199	38.5506
LC-2/ad	GDSC1	-6.9253	2.1034	-9.4133	47.7626
NCI-H2795	GDSC1; GDSC2	-6.9015	-1.4863	-7.8477	39.3345
NCI-H1975	GDSC1; GDSC2	-6.8764	-0.9241	-8.0435	39.7132
RERF-LC-KJ	GDSC1; GDSC2	-6.8592	-4.4574	-6.9419	35.8893
NCI-H1876	GDSC1; GDSC2	-6.8397	-1.8973	-7.6263	38.3416
NCI-H838	GDSC1	-6.8338	-4.7312	-6.8813	44.0897
KNS-62	GDSC1; GDSC2	-6.7582	-1.5807	-7.6584	37.9925
ABC-1	GDSC1	-6.6923	-4.5392	-6.7532	42.4077
NCI-H2804	GDSC1	-6.5511	-2.0739	-7.2512	42.7751
NCI-H2818	GDSC1; GDSC2	-6.544	-1.3719	-7.5123	36.3787
LXF 289	GDSC1; GDSC2	-6.5225	-3.1727	-6.8567	33.7069
EBC-1	GDSC1; GDSC2	-6.4624	-4.3498	-6.5331	31.8684
NCI-H1944	GDSC1; GDSC2	-6.4375	-3.6242	-6.6445	32.2846
NCI-H2110	GDSC1	-6.4076	-3.3001	-6.6954	39.9217
NCI-H1105	GDSC1	-6.3953	-1.1876	-7.4292	42.0864
HCC78	GDSC1; GDSC2	-6.2878	-1.2524	-7.2896	34.2744
SK-MES-1	GDSC1; GDSC2	-6.2352	-3.3628	-6.4902	30.5173
SBC-1	GDSC1	-6.2265	-0.3467	-7.6077	41.3965
RERF-LC-MS	GDSC1	-6.1085	-4.1468	-6.184	35.2816
NCI-H1299	GDSC1; GDSC2	-6.0964	-1.9727	-6.8015	31.3067
HOP-62	GDSC1; GDSC2	-6.0548	-1.776	-6.8334	31.2484
NCI-H1666	GDSC1; GDSC2	-6.031	1.6114	-8.296	36.2837
NCI-H661	GDSC1; GDSC2	-5.9984	-2.0941	-6.6507	30.1378
NCI-H647	GDSC1	-5.9902	-1.3107	-6.9527	37.95
SK-LU-1	GDSC1; GDSC2	-5.8914	-2.0646	-6.5474	29.1358
NCI-H1963	GDSC1; GDSC2	-5.7783	2.1966	-8.324	35.2849
NCI-H209	GDSC1; GDSC2	-5.7749	-1.6116	-6.6029	28.8629
NCI-H1651	GDSC1; GDSC2	-5.7329	-2.9865	-6.0518	25.8662
NCI-H460	GDSC1	-5.7242	-3.8862	-5.814	30.5917
DMS 114	GDSC1; GDSC2	-5.6773	-3.1452	-5.9428	25.0296
NCI-H1915	GDSC1; GDSC2	-5.6617	-1.3474	-6.5937	28.3044
NCI-H522	GDSC2	-5.6583	1.8542	-8.045	33.9699
COR-L311	GDSC2	-5.5958	-1.3306	-6.5322	27.711
NCI-H1755	GDSC1; GDSC2	-5.5403	-0.5428	-6.8184	28.819
NCI-H520	GDSC1; GDSC2	-5.4913	-1.0589	-6.5407	27.292
EPLC-272H	GDSC1; GDSC2	-5.4856	5.6039	-9.6953	37.3308
NCI-H1355	GDSC1; GDSC2	-5.4634	-2.1705	-6.0501	24.6388
NCI-H2030	GDSC1	-5.4383	-1.2294	-6.4121	32.221
SW1271	GDSC1; GDSC2	-5.4176	-1.5565	-6.251	25.5042
NCI-H226	GDSC1; GDSC2	-5.3939	-0.6216	-6.6346	27.3268
NCI-H2170	GDSC1; GDSC2	-5.3878	-1.6825	-6.1671	24.9334
NCI-H2595	GDSC1; GDSC2	-5.3389	-0.3575	-6.6985	27.397
NCI-H82	GDSC1; GDSC2	-5.3188	2.5285	-8.0417	32.5879
NCI-H2009	GDSC1; GDSC2	-5.3089	-1.6003	-6.1192	24.3393
NCI-H847	GDSC1; GDSC2	-5.2885	-2.9251	-5.5882	21.3368
ChaGo-K-1	GDSC1	-5.221	8.4899	-10.8766	41.9285
LB647-SCLC	GDSC1	-5.1194	-0.1944	-6.5545	31.1422
HCC366	GDSC1	-4.9985	-1.3174	-5.9219	27.0384
NCI-H2087	GDSC1; GDSC2	-4.9873	0.1443	-6.583	25.3989
Lu-139	GDSC1	-4.897	2.5806	-7.6704	34.4632
Lu-134-A	GDSC1	-4.858	0.1929	-6.4802	29.4157
UMC-11	GDSC1; GDSC2	-4.7814	0.3151	-6.4645	24.0028
Lu-135	GDSC1; GDSC2	-4.7557	3.2668	-7.8761	29.9122
NCI-H650	GDSC1; GDSC2	-4.721	1.2721	-6.8684	25.7237
NCI-H2085	GDSC1; GDSC2	-4.6957	0.6962	-6.5657	24.1828
NCI-H2731	GDSC1; GDSC2	-4.6888	0.8478	-6.6324	24.484
NCI-H1155	GDSC1; GDSC2	-4.6741	-2.0129	-5.2842	17.0018
Ms-1	GDSC1; GDSC2	-4.629	-1.0241	-5.6835	19.1599
NCI-H2373	GDSC1; GDSC2	-4.6178	0.4008	-6.3492	22.7904
NCI-H1793	GDSC1; GDSC2	-4.4591	1.9864	-6.9746	25.2427
NCI-H810	GDSC1; GDSC2	-4.4212	-0.9107	-5.5327	17.4971
BEN	GDSC1	-4.3628	-0.0087	-5.9097	23.7914
COR-L321	GDSC1	-4.3548	2.7784	-7.2705	30.6068
RERF-LC-Sq1	GDSC1; GDSC2	-4.3215	1.743	-6.7291	23.6104
NCI-H1781	GDSC1; GDSC2	-4.2565	2.0086	-6.8012	23.7249
NCI-H2066	GDSC1; GDSC2	-4.2174	1.2569	-6.3947	21.5774
Lu-99A	GDSC1; GDSC2	-4.1982	-0.061	-5.73	17.8501
NCI-H2810	GDSC1	-4.1952	1.9875	-6.7355	27.5714
NCI-H2081	GDSC1	-4.188	4.874	-8.1623	33.015
NCI-H720	GDSC1; GDSC2	-4.1744	2.0624	-6.7539	23.2151
NCI-H1573	GDSC1; GDSC2	-4.1567	1.2016	-6.3122	20.9358
NCI-H2461	GDSC1; GDSC2	-4.1446	4.2417	-7.8094	27.5574
CAL-12T	GDSC1	-4.1423	0.021	-5.7182	21.5654
IST-SL2	GDSC1; GDSC2	-4.1364	4.6386	-7.9998	28.2128
NCI-H3255	GDSC1	-4.08	20.5382	-15.8894	42.8901
NCI-H1694	GDSC1; GDSC2	-4.0478	2.7883	-7.0012	23.9322
NCI-H69	GDSC1; GDSC2	-3.9908	0.3398	-5.7362	17.1727
COR-L279	GDSC1; GDSC2	-3.9527	-1.182	-4.9542	12.32
SHP-77	GDSC1; GDSC2	-3.8948	-2.6362	-4.2106	7.549
NCI-H1341	GDSC1; GDSC2	-3.8878	1.2632	-6.1016	18.8936
NCI-H1734	GDSC1	-3.8059	1.2805	-6.0379	22.1353
Calu-6	GDSC1; GDSC2	-3.7385	4.1391	-7.4051	24.6646
COR-L32	GDSC2	-3.7124	3.8717	-7.2491	23.9265
NCI-H64	GDSC1; GDSC2	-3.6154	3.5102	-6.9855	22.4543
NCI-H187	GDSC1	-3.5299	2.3044	-6.3102	22.6126
NCI-H358	GDSC1; GDSC2	-3.4797	1.6194	-5.9252	16.6093
IA-LM	GDSC1; GDSC2	-3.4107	2.2159	-6.1652	17.724
NCI-H2141	GDSC1; GDSC2	-3.3464	0.9898	-5.4982	13.7224
NCI-H2227	GDSC1	-3.2654	1.2441	-5.558	16.9298
NCI-H2023	GDSC1; GDSC2	-3.2136	2.9465	-6.3664	18.1994
NCI-H1688	GDSC1; GDSC2	-3.1778	3.2329	-6.48	18.6784
NCI-H1436	GDSC1	-3.177	2.7292	-6.2276	20.8114
COR-L95	GDSC1	-3.1276	-1.1562	-4.2474	6.6238
COR-L88	GDSC1; GDSC2	-3.0188	3.6237	-6.5455	18.5461
PaCa-3	GDSC1; GDSC2	-3.0015	2.9135	-6.1768	16.5795
NCI-H2228	GDSC1; GDSC2	-2.9147	8.2667	-8.7804	27.1415
NCI-H1993	GDSC1; GDSC2	-2.9039	0.5759	-4.9343	9.0337
NCI-H1770	GDSC1	-2.7112	4.1955	-6.5846	21.1431
COLO 668	GDSC1; GDSC2	-2.6949	1.4406	-5.203	10.1386
NCI-H835	GDSC1; GDSC2	-2.522	7.5154	-8.0893	23.7875
NCI-H146	GDSC1	-2.3287	3.9379	-6.161	17.5503
NCI-H1838	GDSC1; GDSC2	-2.3186	2.8861	-5.6346	11.7411
NCI-H1693	GDSC1; GDSC2	-2.2614	4.0817	-6.1814	14.6166
NCI-H2722	GDSC1; GDSC2	-2.0565	3.1843	-5.5902	10.8589
COR-L105	GDSC1; GDSC2	-1.8932	5.1375	-6.428	14.9822
EKVX	GDSC1	-1.8733	3.5812	-5.6534	13.0752
NCI-H345	GDSC1	-1.5095	3.8977	-5.5559	11.4695
NCI-H2029	GDSC1	-1.4823	4.4037	-5.78	12.809
NCI-H1092	GDSC1; GDSC2	-1.4609	4.3351	-5.7325	10.3273
SW1573	GDSC1; GDSC2	-1.4305	6.5313	-6.775	15.5853
NCI-H2869	GDSC1	-1.4001	11.2653	-9.0824	27.0737
NCI-H2347	GDSC1; GDSC2	-1.3906	3.8867	-5.4717	8.7443
NCI-H2135	GDSC1	-1.2498	2.3209	-4.6609	4.9642
HCC827	GDSC1; GDSC2	-1.1069	10.1575	-8.3166	21.1654
NCI-H596	GDSC1; GDSC2	-1.0104	5.2636	-5.8749	10.163
HOP-92	GDSC1; GDSC2	-1.002	5.7686	-6.1095	11.3657
Lu-65	GDSC1; GDSC2	-0.9311	5.8477	-6.1	11.1727
NCI-H1623	GDSC1; GDSC2	-0.9029	5.5903	-5.9592	10.39
NCI-H2444	GDSC1	-0.8226	4.6868	-5.4846	9.3735
NCI-H322M	GDSC1; GDSC2	-0.6442	10.8177	-8.3034	20.111
NCI-H2591	GDSC1; GDSC2	-0.6115	9.9607	-7.8623	18.4127
NCI-H1836	GDSC1	-0.5447	2.2427	-4.2704	1.6802
NCI-H1869	GDSC1; GDSC2	-0.4653	7.8505	-6.7442	13.3729
NCI-H196	GDSC1; GDSC2	-0.4313	4.8995	-5.3467	6.337
NCI-H2291	GDSC1	-0.3798	7.9283	-6.7245	15.3164
NCI-H513	GDSC1; GDSC2	-0.2855	9.4355	-7.3819	15.8129
NCI-H1568	GDSC1; GDSC2	-0.2495	6.6562	-6.0422	9.5778
NCI-H2172	GDSC1	-0.2406	6.327	-5.8843	10.4918
DMS 79	GDSC1	-0.24	4.2244	-4.9418	4.9298
NCI-H727	GDSC1; GDSC2	-0.0724	12.764	-8.844	20.7623
NCI-H2342	GDSC1; GDSC2	0.0235	4.5545	-4.9455	3.6964
NCI-H2803	GDSC1	0.0385	2.045	-3.9664	0.2844
NCI-H1650	GDSC1; GDSC2	0.0777	5.3865	-5.2758	5.2149
Lu-165	GDSC1; GDSC2	0.1358	2.3382	-4.0325	0.3145
NCI-H1304	GDSC1	0.145	8.5376	-6.6714	13.8682
Calu-3	GDSC1; GDSC2	0.2436	3.6465	-4.471	1.4793
NCI-H1563	GDSC1; GDSC2	0.2691	9.651	-7.1153	13.6092
NCI-H1435	GDSC1; GDSC2	0.3587	6.3127	-5.5279	6.046
DMS 53	GDSC1; GDSC2	0.452	2.5497	-3.9928	0.1822
NCI-H2405	GDSC1; GDSC2	0.6278	3.1067	-4.1208	0.3365
NCI-H441	GDSC1; GDSC2	0.6632	12.823	-8.3633	17.7289

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
CBTCi002-A	GDSC1; GDSC2	-3.152	0.1151	-4.9009	9.498

Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Oesophagus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TE-4	GDSC1; GDSC2	-8.7091	-7.8712	-8.7091	54.0604
EC-GI-10	GDSC1; GDSC2	-8.534	-6.416	-8.5426	52.2772
OE21	GDSC1; GDSC2	-8.249	-3.2499	-8.7188	49.5557
T.T	GDSC1; GDSC2	-8.2253	-4.3429	-8.4329	49.2951
TE-8	GDSC1; GDSC2	-7.8875	-6.0989	-7.8934	45.8348
TE-11	GDSC1	-7.5769	-4.9821	-7.6395	52.9771
KYSE-510	GDSC1	-7.3249	0.7007	-9.1947	50.0185
TE-9	GDSC1; GDSC2	-7.1344	-5.35	-7.1492	38.329
KYSE-180	GDSC1; GDSC2	-6.9656	-4.619	-7.0338	36.8838
TE-5	GDSC1; GDSC2	-6.8685	-3.3881	-7.1746	36.9262
KYSE-450	GDSC1; GDSC2	-6.7555	-3.9573	-6.9167	35.2152
TE-1	GDSC1; GDSC2	-6.6569	-2.6575	-7.1624	35.7069
KYSE-410	GDSC1; GDSC2	-6.268	-3.2727	-6.5506	30.9761
TE-10	GDSC1	-5.6234	-3.1753	-5.8751	30.3464
TE-15	GDSC1	-5.6063	-3.2502	-5.8348	29.994
OE19	GDSC1; GDSC2	-5.4003	8.3588	-10.9734	39.1473
KYSE-150	GDSC1; GDSC2	-4.6908	-1.2042	-5.662	19.2735
TE-6	GDSC1; GDSC2	-4.3988	0.4746	-6.1784	21.0794
KYSE-520	GDSC1; GDSC2	-4.2354	3.152	-7.3485	26.0694
KYSE-270	GDSC1; GDSC2	-4.1575	1.4793	-6.4501	21.6545
KYSE-140	GDSC1; GDSC2	-3.9331	3.1102	-7.0605	23.8167
KYSE-70	GDSC1; GDSC2	-3.669	1.7588	-6.157	18.4856
OE33	GDSC1; GDSC2	-3.2243	12.4272	-11.1153	33.4818
COLO 680N	GDSC1; GDSC2	-1.331	8.3771	-7.6065	18.992

Cancer Drug Sensitivity Data Curated from 29 Cell Line(s) in Ovary Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TOV-112D	GDSC1; GDSC2	-8.4634	-4.9013	-8.594	51.4539
A2780	GDSC1; GDSC2	-8.2913	-4.4347	-8.4869	49.8824
OVCAR-3	GDSC1; GDSC2	-7.8739	-4.1901	-8.0824	46.1046
OC 314	GDSC1; GDSC2	-7.8416	-5.9583	-7.8504	45.3847
OVCAR-8	GDSC1; GDSC2	-7.4549	-5.565	-7.4689	41.5355
OVK18	GDSC1	-7.1156	-3.4067	-7.4392	47.8626
EFO-27	GDSC1	-7.0455	-2.0626	-7.7878	47.5577
OVTOKO	GDSC1; GDSC2	-6.5903	1.1015	-8.6211	39.6075
TOV-21G	GDSC1; GDSC2	-6.5435	-2.7749	-7.001	34.4428
TYK-nu	GDSC1; GDSC2	-6.3359	-2.6826	-6.8056	32.515
DOV13	GDSC1; GDSC2	-6.1485	-3.8692	-6.2763	29.0155
OVCAR-5	GDSC1; GDSC2	-6.1089	-3.7045	-6.2681	28.7798
OVISE	GDSC1; GDSC2	-5.9652	-1.8763	-6.6988	30.2049
JHOS-2	GDSC1	-5.8093	-3.7847	-5.9256	31.8131
ES-2	GDSC1; GDSC2	-5.7943	-3.5969	-5.9503	25.6179
SK-OV-3	GDSC1; GDSC2	-5.6597	-0.2009	-7.0929	30.5426
OV56	GDSC1; GDSC2	-5.4017	-2.6329	-5.8111	23.0665
JHOS-4	GDSC1	-5.2937	-2.066	-5.9112	28.608
OV-90	GDSC1; GDSC2	-5.1548	0.1811	-6.7645	26.9427
IGROV-1	GDSC1; GDSC2	-4.6846	-1.8341	-5.3727	17.5621
RMG-I	GDSC1; GDSC2	-3.1947	1.6969	-5.7262	14.6177
Kuramochi	GDSC1; GDSC2	-3.0888	1.8967	-5.7396	14.39
OAW42	GDSC1; GDSC2	-2.6062	-0.2426	-4.3136	4.4774
EFO-21	GDSC1; GDSC2	-2.5809	1.3014	-5.0488	8.9173
OVCAR-4	GDSC1; GDSC2	-2.2359	8.0256	-8.1179	23.1485
Caov-4	GDSC1; GDSC2	-1.4789	4.59	-5.8672	11.0968
OAW28	GDSC1; GDSC2	-1.0159	9.3467	-7.8523	19.2502
OVKATE	GDSC1; GDSC2	-0.39	4.3037	-5.0575	4.792
FU-OV-1	GDSC1; GDSC2	-0.1035	6.8238	-6.0295	9.2556

Cancer Drug Sensitivity Data Curated from 31 Cell Line(s) in Pancreas Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
PSN1	GDSC1; GDSC2	-8.6575	-3.9396	-8.9886	52.9074
KP-4	GDSC1; GDSC2	-8.3236	-6.8421	-8.3244	50.1921
MIA PaCa-2	GDSC1; GDSC2	-7.3184	-2.9765	-7.7824	41.6248
BxPC-3	GDSC1; GDSC2	-7.0348	-4.1041	-7.1902	37.9388
Panc 03.27	GDSC1; GDSC2	-7.0162	-2.7379	-7.527	39.0377
Panc 02.03	GDSC1; GDSC2	-6.5733	-1.9187	-7.3325	35.9015
PaTu 8988t	GDSC1; GDSC2	-6.2897	-4.1692	-6.3749	30.2121
KP-1N	GDSC1; GDSC2	-6.2504	0.9227	-8.1974	37.0006
KP-2	GDSC1; GDSC2	-6.224	-1.9821	-6.9344	32.5204
AsPC-1	GDSC1; GDSC2	-6.1797	4.2934	-9.7119	39.8997
HuP-T3	GDSC1; GDSC2	-5.8948	0.005	-7.4236	32.9027
HPAC	GDSC1; GDSC2	-5.7864	-3.0137	-6.1015	26.3776
PaTu 8902	GDSC1; GDSC2	-5.7392	-2.0086	-6.4067	27.7353
MZ-PC-1	GDSC1	-5.4779	0.0829	-7.0392	35.1929
KP-3	GDSC1; GDSC2	-5.0152	-0.863	-6.1431	23.2466
Capan-1	GDSC1; GDSC2	-4.7861	-0.6011	-6.0357	21.7547
SU.86.86	GDSC1; GDSC2	-4.5333	1.325	-6.7188	24.3237
HuP-T4	GDSC1; GDSC2	-3.635	-0.3889	-5.0569	11.909
SUIT-2	GDSC1; GDSC2	-3.0255	0.233	-4.8588	8.8876
HPAF-II	GDSC1; GDSC2	-3.0057	2.6154	-6.0314	15.7998
YAPC	GDSC1; GDSC2	-2.7542	0.9906	-5.0252	9.2069
PL4	GDSC1; GDSC2	-2.5295	5.1034	-6.8938	18.8727
Panc 10.05	GDSC1; GDSC2	-2.3807	3.8044	-6.1343	14.6699
Capan-2	GDSC1; GDSC2	-2.3182	1.5889	-4.9994	7.9965
CFPAC-1	GDSC1; GDSC2	-2.2455	4.7219	-6.4857	16.1481
SW1990	GDSC1; GDSC2	-2.122	7.5364	-7.7863	21.6158
Hs 766T	GDSC1; GDSC2	-1.7939	5.7201	-6.6413	15.7988
Panc 04.03	GDSC1; GDSC2	-0.8503	9.2004	-7.6619	18.1396
QGP-1	GDSC1	-0.7037	6.5225	-6.2704	13.7083
DAN-G	GDSC1; GDSC2	-0.5454	7.9432	-6.8423	13.9855
Panc 08.13	GDSC1; GDSC2	-0.4991	7.5662	-6.6313	12.9139

Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Pleura Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
NCI-H2452	GDSC1; GDSC2	-6.8417	-2.861	-7.2983	37.245
NCI-H2052	GDSC1; GDSC2	-6.3329	-0.4546	-7.671	35.836
MSTO-211H	GDSC1; GDSC2	-5.2953	2.9533	-8.225	33.0656
MPP 89	GDSC1; GDSC2	-5.2826	-0.0524	-6.7822	27.5524
NCI-H28	GDSC1; GDSC2	-3.4931	4.1397	-7.1963	23.0132
IST-Mes1	GDSC1; GDSC2	-0.4657	10.3739	-7.9602	18.4794

Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Prostate Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
LNCaP clone FGC	GDSC1; GDSC2	-6.6896	-2.5933	-7.2192	36.1046
22Rv1	GDSC1; GDSC2	-6.4879	-3.6656	-6.6897	32.7586
PC-3	GDSC1; GDSC2	-6.1657	-3.588	-6.3571	29.5099
VCaP	GDSC1; GDSC2	-6.1292	-3.3408	-6.3805	29.4494
DU145	GDSC1; GDSC2	-3.9995	-0.8431	-5.1632	13.7674

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Salivary Gland Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
A-253	GDSC1; GDSC2	-5.5333	-0.0536	-7.0323	29.7331

Cancer Drug Sensitivity Data Curated from 57 Cell Line(s) in Skin Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
LOX-IMVI	GDSC1; GDSC2	-8.6633	-4.651	-8.8495	53.1576
RPMI-7951	GDSC1; GDSC2	-8.4373	-5.5272	-8.4919	51.2729
A2058	GDSC1; GDSC2	-8.2812	-7.2536	-8.2813	49.7672
G-mel	GDSC1	-8.2671	-4.4247	-8.4626	59.5579
A-375	GDSC1; GDSC2	-8.2097	-5.7258	-8.2393	49.0722
WM35	GDSC1; GDSC2	-7.8713	-2.0818	-8.6734	46.797
SK-MEL-5	GDSC1	-7.735	-3.4876	-8.0938	53.9994
COLO 800	GDSC1	-7.6317	-6.6992	-7.6317	53.8711
451Lu	GDSC1	-7.5879	-0.1048	-9.1274	51.7545
SK-MEL-2	GDSC1; GDSC2	-7.494	-3.7164	-7.7737	42.7442
CHL-1	GDSC1; GDSC2	-7.443	-5.2588	-7.474	41.4839
UACC-62	GDSC1; GDSC2	-7.4003	-5.5511	-7.4134	40.9848
WM793	GDSC1; GDSC2	-7.2875	-1.5599	-8.2323	42.467
RVH-421	GDSC1	-7.2387	4.1357	-10.6652	49.6168
HT-144	GDSC1; GDSC2	-7.2197	-3.3182	-7.5767	40.4201
IGR-37	GDSC1; GDSC2	-7.0737	-5.2381	-7.0922	37.7382
A-431	GDSC1	-6.9642	-4.7786	-7.014	45.6889
M14	GDSC1; GDSC2	-6.7478	-4.1214	-6.8766	34.9922
CP50-MEL-B	GDSC1	-6.7092	-2.737	-7.1934	43.8725
WM278	GDSC1; GDSC2	-6.6313	-2.2576	-7.2715	35.9861
MeWo	GDSC1; GDSC2	-6.5597	-4.3295	-6.64	32.8886
A101D	GDSC1; GDSC2	-6.4064	-1.0862	-7.4824	35.569
IPC-298	GDSC1	-6.3518	-3.8169	-6.5077	38.6877
DJM-1	GDSC1	-6.3454	-2.0266	-7.0477	40.6931
Mel Ho	GDSC1	-6.3404	-2.6835	-6.8102	39.8558
COLO 829	GDSC1; GDSC2	-6.2499	0.2935	-7.9134	36.1915
IST-MEL1	GDSC1; GDSC2	-6.2078	-0.8975	-7.3527	34.1163
MMAc-SF	GDSC1	-6.1139	-0.3604	-7.4858	40.3864
HMV-II	GDSC1; GDSC2	-6.083	2.0327	-8.5441	37.1477
A-388	GDSC1	-6.0104	-1.7923	-6.7798	37.4301
Hs 938.T	GDSC1	-5.9832	-1.4102	-6.9045	37.7282
SK-MEL-28	GDSC1	-5.9148	-2.9708	-6.2548	34.3767
WM115	GDSC1; GDSC2	-5.7618	3.5385	-8.95	36.7921
IGR-1	GDSC1; GDSC2	-5.7587	-1.8568	-6.4871	28.225
WM1552C	GDSC1; GDSC2	-5.6256	-3.0704	-5.9089	24.6097
COLO 783	GDSC1	-5.5914	-0.4079	-6.9307	35.4212
WT2-iPS	GDSC1; GDSC2	-5.5101	2.5978	-8.2573	34.0038
COLO 679	GDSC1; GDSC2	-5.2536	-1.1376	-6.2621	24.8615
COLO 792	GDSC1; GDSC2	-5.0126	-1.9366	-5.6686	20.6013
G-361	GDSC1; GDSC2	-4.8423	-1.7008	-5.593	19.4734
MZ-MEL-2	GDSC1	-4.7816	1.2653	-6.9223	31.1085
VMRC-MELG	GDSC1	-4.6794	0.9422	-6.6693	29.4652
SH-4	GDSC1; GDSC2	-4.6269	0.3417	-6.3293	22.7212
SK-MEL-31	GDSC1	-4.5192	0.1637	-6.1411	25.9135
SK-MEL-24	GDSC1; GDSC2	-4.0461	0.9006	-6.0634	19.2145
LB2518-MEL	GDSC1	-3.8804	-0.201	-5.3692	18.0447
SK-MEL-30	GDSC1	-3.5646	15.0912	-12.7315	39.3019
Hs 940.T	GDSC1	-3.3507	3.4563	-6.7351	24.1747
UACC-257	GDSC1; GDSC2	-3.1338	3.8045	-6.7296	19.7873
Mel JuSo	GDSC1; GDSC2	-2.4906	5.22	-6.9214	18.8972
GAK	GDSC1; GDSC2	-2.4298	2.3859	-5.4708	11.0667
CP66-MEL	GDSC1	-1.3147	11.1792	-8.9752	26.5389
LB373-MEL-D	GDSC1	-1.0644	9.849	-8.1338	23.1031
SK-MEL-1	GDSC1; GDSC2	-1.012	8.8797	-7.6212	18.331
MZ-MEL-7	GDSC1	-0.4044	2.7327	-4.4012	2.1661
SK-MEL-3	GDSC1	0.5445	9.9467	-7.0773	14.952
EquiPSC Line K2	GDSC1	-4.2482	2.1083	-6.843	28.3094

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HuTu 80	GDSC1	-6.4827	-4.8714	-6.5021	39.6193

Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Soft Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
EW-8	GDSC1; GDSC2	-8.0595	-6.8276	-8.0597	47.5424
SW982	GDSC1; GDSC2	-8.0407	-5.4546	-8.0827	47.4297
KYM-1	GDSC1; GDSC2	-8.0208	-5.6042	-8.0511	47.2151
Rh41	GDSC1; GDSC2	-7.869	-4.8486	-7.9661	45.8607
GCT	GDSC1; GDSC2	-7.8101	-5.2805	-7.8559	45.1724
HT-1080	GDSC1; GDSC2	-7.7633	-6.4125	-7.7642	44.5736
SK-LMS-1	GDSC1; GDSC2	-7.7443	-4.74	-7.848	44.6728
G-401	GDSC1; GDSC2	-7.4746	-4.3066	-7.628	42.2079
VA-ES-BJ	GDSC1; GDSC2	-7.4603	-1.7827	-8.3356	43.7045
RD	GDSC1; GDSC2	-7.3893	-4.0247	-7.5906	41.5365
RKN	GDSC1; GDSC2	-7.0721	-4.9481	-7.1113	37.8163
SK-UT-1	GDSC1; GDSC2	-6.7963	-4.7439	-6.8405	35.0814
Hs 633.T	GDSC1; GDSC2	-6.5812	-4.6188	-6.6265	32.932
STS-0421	GDSC1	-6.5459	-0.5895	-7.835	43.935
G-402	GDSC1; GDSC2	-6.2816	-0.6547	-7.5323	35.1198
A-204	GDSC1; GDSC2	-6.0774	-2.4353	-6.6106	30.3273
MFH-ino	GDSC1; GDSC2	-5.5469	-1.2133	-6.5314	27.4906
MES-SA	GDSC1; GDSC2	-5.37	-1.2357	-6.3388	25.7536
Rh30	GDSC1; GDSC2	-5.1848	-1.1678	-6.1783	24.1314
SW872	GDSC1; GDSC2	-4.0967	-1.0776	-5.1408	13.9688
SW684	GDSC1; GDSC2	-3.5005	1.986	-6.1261	17.788
Rh18	GDSC1	0.6024	12.2791	-8.1441	19.2506

Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Stomach Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HGC-27	GDSC1; GDSC2	-9.1897	-5.618	-9.2753	58.0572
TMK-1	GDSC1	-7.7605	-5.9186	-7.7689	55.3865
MKN28	GDSC1; GDSC2	-7.4751	-0.3173	-8.9215	44.6584
NUGC-3	GDSC1; GDSC2	-7.429	-4.3168	-7.5769	41.7508
SNU-16	GDSC1; GDSC2	-7.3264	-4.057	-7.5156	40.8957
HSC-39	GDSC1; GDSC2	-7.3158	-5.7862	-7.3203	40.1
SK-GT-2	GDSC1; GDSC2	-6.9627	-3.1102	-7.3549	38.1422
23132/87	GDSC1; GDSC2	-6.9016	-5.906	-6.902	35.9242
IM95	GDSC1; GDSC2	-6.6719	-4.3479	-6.7575	34.0351
RERF-GC-1B	GDSC1; GDSC2	-6.6127	-3.4381	-6.8822	34.2966
AGS	GDSC1; GDSC2	-6.589	-2.7483	-7.0591	34.9261
RF-48	GDSC1; GDSC2	-6.5122	-2.5129	-7.0539	34.4976
NCI-N87	GDSC1; GDSC2	-6.4379	1.0882	-8.4613	38.5348
TGBC11TKB	GDSC1; GDSC2	-5.8681	-0.5799	-7.1372	31.6662
MKN1	GDSC1; GDSC2	-5.8625	-0.5278	-7.1543	31.7099
SNU-1	GDSC1; GDSC2	-5.6486	0.9808	-7.6246	32.5413
ECC10	GDSC1; GDSC2	-5.5657	0.725	-7.4234	31.4496
MKN45	GDSC1; GDSC2	-5.4102	-1.4698	-6.28	25.6232
SCH	GDSC1	-4.9721	-1.2328	-5.9326	26.9627
OCUM-1	GDSC1; GDSC2	-4.5859	-0.003	-6.1245	21.4758
KATO III	GDSC1; GDSC2	-4.5575	-0.7715	-5.7313	19.1642
SNU-5	GDSC1; GDSC2	-4.3229	1.0283	-6.3787	21.8668
GCIY	GDSC1; GDSC2	-3.2811	1.1842	-5.5411	13.7843
Fu97	GDSC1; GDSC2	-3.1604	7.1144	-8.4061	26.6283
Hs 746.T	GDSC1; GDSC2	-2.6532	6.8837	-7.8787	23.3594
MKN7	GDSC1; GDSC2	-1.5781	2.8586	-5.1078	7.0673
NUGC-4	GDSC1; GDSC2	-1.3893	4.0715	-5.5586	9.2229
SNG-M	GDSC1; GDSC2	-7.6746	-5.855	-7.6832	43.713

Cancer Drug Sensitivity Data Curated from 16 Cell Line(s) in Thyroid Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
KMH-2	GDSC1	-8.9253	-7.252	-8.9262	69.6472
IHH-4	GDSC1; GDSC2	-8.2637	-6.1044	-8.2764	49.5959
B-CPAP	GDSC1; GDSC2	-8.2253	-6.0592	-8.2388	49.2157
CGTH-W-1	GDSC1; GDSC2	-8.1689	-5.3483	-8.2264	48.6949
8505C	GDSC1; GDSC2	-8.1227	-4.8609	-8.2353	48.2995
K5	GDSC1; GDSC2	-7.4573	-5.3372	-7.4835	41.6084
8305C	GDSC1; GDSC2	-7.3154	-2.8611	-7.8141	41.6885
FTC-133	GDSC1; GDSC2	-6.9993	-4.2284	-7.129	37.484
CAL-62	GDSC1; GDSC2	-6.8163	-4.1125	-6.9523	35.7038
ML-1 [Human leukemia]	GDSC1	-6.6999	-2.1883	-7.3701	44.1842
HTC-C3	GDSC1; GDSC2	-6.5045	-4.0293	-6.6307	32.5611
WRO	GDSC1; GDSC2	-6.2876	-0.8576	-7.4528	34.8714
ASH-3	GDSC1; GDSC2	-5.7798	-2.1533	-6.3944	27.86
BHT-101	GDSC1; GDSC2	-4.868	-2.2456	-5.3892	18.4031
TT2609-C02	GDSC1; GDSC2	-3.4212	-1.1032	-4.5151	7.8474
TT	GDSC1; GDSC2	-1.9761	6.0692	-6.9485	17.6969

Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Upper Aerodigestive Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
KOSC-2	GDSC1	-9.6854	-6.1321	-9.7474	73.667
PCI-06A	GDSC1	-8.8419	-7.2979	-8.8424	68.7488
HO-1-N-1	GDSC1; GDSC2	-8.718	-5.4678	-8.7931	53.8702
CAL-27	GDSC1; GDSC2	-8.7006	-7.5879	-8.7006	53.975
JHU-011	GDSC1	-8.6597	-5.8425	-8.699	65.0761
JHU-029	GDSC1	-8.6105	-6.3728	-8.6217	65.3189
BICR 22	GDSC1; GDSC2	-8.4006	-5.4479	-8.4606	50.9183
SCC-4	GDSC1; GDSC2	-8.2319	-3.9787	-8.5163	49.3753
HSC-3	GDSC1; GDSC2	-8.0915	-0.1548	-9.6372	48.7231
HSC-4	GDSC1; GDSC2	-8.0119	-3.0503	-8.5169	47.6474
CAL-33	GDSC1; GDSC2	-7.8394	-5.6685	-7.8597	45.3958
PCI-38	GDSC1	-7.8388	-5.3742	-7.8781	56.0935
DOK	GDSC1; GDSC2	-7.8255	-5.1825	-7.8811	45.3477
PCI-04B	GDSC1	-7.7833	-5.5521	-7.8081	55.5393
NCI-H3118	GDSC1; GDSC2	-7.6073	-5.8331	-7.6153	43.0372
Ca9-22	GDSC1; GDSC2	-7.599	-6.2076	-7.6004	42.9271
Detroit 562	GDSC1; GDSC2	-7.5753	-5.2117	-7.6158	42.8351
BB30-HNC	GDSC1	-7.5278	-4.89	-7.5979	52.3947
KON	GDSC1	-7.4663	-4.4807	-7.5893	51.6238
BICR 10	GDSC1; GDSC2	-7.4089	-4.2646	-7.5647	41.5821
BICR 78	GDSC1; GDSC2	-7.1005	-2.6755	-7.6387	39.8834
OSC-19	GDSC1	-6.949	-4.4678	-7.0364	45.6045
BB49-HNC	GDSC1; GDSC2	-6.6206	-3.6462	-6.8388	34.143
PE/CA-PJ15	GDSC1	-6.5861	-1.2956	-7.5872	43.7642
SCC-9	GDSC1; GDSC2	-6.4937	-4.2006	-6.5891	32.3032
BHY	GDSC1	-6.3566	-1.5484	-7.2436	41.3433
SKN-3	GDSC1; GDSC2	-6.2224	-0.6552	-7.4706	34.6146
FaDu	GDSC1; GDSC2	-6.1362	-2.0586	-6.8116	31.5464
SCC-25	GDSC1	-6.1151	-2.8833	-6.5003	36.9533
SAT [Human HNSCC]	GDSC1; GDSC2	-5.8907	0.9298	-7.8408	34.3244
HO-1-u-1	GDSC1; GDSC2	-5.8357	-1.4547	-6.7311	29.7478
OSC-20	GDSC1; GDSC2	-5.741	-1.7411	-6.5147	28.28
HSC-2	GDSC1; GDSC2	-5.7025	-2.3945	-6.2213	26.6175
UPCI-SCC-090	GDSC1; GDSC2	-4.6737	1.4355	-6.9035	25.7067
LB771-HNC	GDSC1; GDSC2	-4.5967	5.6255	-8.8979	32.489
SAS	GDSC1; GDSC2	-4.5528	2.0652	-7.0993	26.1337
SCC-15	GDSC1; GDSC2	-4.2717	2.8771	-7.2447	25.7609
JHU-022	GDSC1; GDSC2	-4.0016	8.7776	-9.947	33.1976
PCI-30	GDSC1; GDSC2	-3.8177	12.0483	-11.424	35.4691
PCI-15A	GDSC1	-3.1168	-0.8312	-4.4007	7.7887

Cancer Drug Sensitivity Data Curated from 16 Cell Line(s) in Urinary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
5637	GDSC1; GDSC2	-9.1782	-7.0784	-9.1823	58.6594
RT-112	GDSC1; GDSC2	-8.3569	-6.6467	-8.3593	50.5247
BFTC-905	GDSC1; GDSC2	-8.2344	-5.3368	-8.2965	49.3286
T24	GDSC1	-7.9816	-2.8391	-8.5468	55.6988
SW780	GDSC1; GDSC2	-7.9794	-4.2879	-8.1774	47.06
SW1710	GDSC1; GDSC2	-7.4427	-4.9746	-7.4986	41.5743
639V	GDSC1; GDSC2	-7.1159	-3.5036	-7.4142	39.2551
UM-UC-3	GDSC1; GDSC2	-6.8337	-4.6126	-6.8945	35.5332
CAL-29	GDSC1; GDSC2	-6.767	-1.444	-7.7207	38.2302
KU-19-19	GDSC1; GDSC2	-5.2851	-1.2873	-6.2289	24.8199
TCCSUP	GDSC1; GDSC2	-5.0186	-0.6248	-6.2554	23.8582
RT-4	GDSC1; GDSC2	-4.2267	7.6391	-9.5736	33.0123
647V	GDSC1; GDSC2	-3.747	-0.1309	-5.2842	13.6674
J82	GDSC1; GDSC2	-2.516	0.0534	-4.3943	4.7723
HT-1376	GDSC1; GDSC2	-2.0332	4.9021	-6.4156	15.261
HT-1197	GDSC1; GDSC2	-1.2005	5.1917	-5.9669	11.0356

Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Urogenital System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
NCC-IT	GDSC2	-10.0377	-7.3132	-10.0487	66.5749
JAR	GDSC1	-8.2505	-5.7909	-8.2776	60.9049
HEY	GDSC1; GDSC2	-8.2261	-5.0769	-8.3168	49.2615
BPH-1	GDSC1; GDSC2	-7.8751	-5.203	-7.9314	45.8355
PWR-1E	GDSC1; GDSC2	-7.853	-4.962	-7.9345	45.6744
CAL-39	GDSC1; GDSC2	-7.776	-6.0214	-7.782	44.719
NT2-D1	GDSC1; GDSC2	-7.6952	-6.2826	-7.6966	43.8921
PA-1	GDSC1; GDSC2	-7.6857	-6.36	-7.6866	43.7945
MS751	GDSC1; GDSC2	-7.6288	-5.4467	-7.6544	43.3159
Ca Ski	GDSC1; GDSC2	-7.4427	-4.3852	-7.5798	41.8492
TC-YIK	GDSC1; GDSC2	-7.4339	-4.3732	-7.5723	41.7683
SKN	GDSC1; GDSC2	-7.3701	-2.8687	-7.8715	42.1791
HeLa	GDSC1; GDSC2	-7.3534	-4.3883	-7.4831	40.9568
SiSo	GDSC1; GDSC2	-7.2129	-5.524	-7.2225	39.0918
SW954	GDSC1	-7.1119	-4.6831	-7.1814	47.5125
JEG-3	GDSC1	-6.841	-5.3883	-6.8474	44.0193
C-33 A	GDSC1; GDSC2	-6.8096	-4.1816	-6.9326	35.5788
C-4-I	GDSC1; GDSC2	-6.6171	-5.3157	-6.6216	33.09
NEC8	GDSC1; GDSC2	-6.5166	-3.342	-6.8029	33.4335
PEO1	GDSC1; GDSC2	-6.4609	-3.6038	-6.6749	32.5494
OVMIU	GDSC1; GDSC2	-6.1113	-1.4544	-7.0214	32.3363
SW962	GDSC1	-6.0336	-2.4629	-6.5534	36.634
SW756	GDSC1; GDSC2	-5.9555	1.6724	-8.25	35.83
ME-180	GDSC1; GDSC2	-5.8796	-2.0239	-6.5504	29.0954
OVCA433	GDSC1	-5.4683	2.2339	-8.0426	38.2503
KGN	GDSC1; GDSC2	-5.4439	-1.6055	-6.258	25.6553
HEC-1	GDSC1; GDSC2	-5.3803	1.9579	-7.826	32.1228
DoTc2 4510	GDSC1; GDSC2	-5.2476	-0.6866	-6.4573	25.8373
LB831-BLC	GDSC1; GDSC2	-5.1298	-0.1358	-6.592	26.0171
SKG-IIIa	GDSC1; GDSC2	-4.9745	-1.3354	-5.8893	21.6904
DSH1	GDSC1; GDSC2	-4.5231	2.257	-7.1663	26.3152
HT-3	GDSC1; GDSC2	-4.406	-0.1315	-5.8911	19.5171
ACC-OV7	GDSC1	-4.3671	4.1108	-7.9416	33.0433
UWB1.289	GDSC1	-4.166	-0.4157	-5.527	20.3896
OVCA420	GDSC1; GDSC2	-3.0036	-0.3779	-4.5378	6.8188
OMC-1 [Human cervical carcinoma]	GDSC1	-2.8974	4.5815	-6.9257	23.4832
OV17R	GDSC1	-2.7489	-0.6219	-4.2293	5.3263
SiHa	GDSC1; GDSC2	-1.719	3.4261	-5.4716	9.4277
JHOS-3	GDSC1	-0.9108	2.6914	-4.6366	4.2027

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Vinblastine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Vinblastine caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[17]
Armodafinil	DMGB035	Minor	Increased metabolism of Vinblastine caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[18]
LEE011	DMMX75K	Moderate	Decreased metabolism of Vinblastine caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[19]
Etoposide	DMNH3PG	Minor	Decreased metabolism of Vinblastine caused by Etoposide mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[20]
Doxorubicin	DMVP5YE	Minor	Decreased metabolism of Vinblastine caused by Doxorubicin mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[20]

Coadministration of a Drug Treating the Disease Different from Vinblastine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Vinblastine caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[21]
Midostaurin	DMI6E0R	Moderate	Decreased clearance of Vinblastine due to the transporter inhibition by Midostaurin.	Acute myeloid leukaemia [2A60]	[22]
Gilteritinib	DMTI0ZO	Moderate	Decreased clearance of Vinblastine due to the transporter inhibition by Gilteritinib.	Acute myeloid leukaemia [2A60]	[17]
Siltuximab	DMGEATB	Moderate	Additive myelosuppressive effects by the combination of Vinblastine and Siltuximab.	Anemia [3A00-3A9Z]	[22]
Dronedarone	DMA8FS5	Moderate	Decreased clearance of Vinblastine due to the transporter inhibition by Dronedarone.	Angina pectoris [BA40]	[23]
Voriconazole	DMAOL2S	Major	Decreased clearance of Vinblastine due to the transporter inhibition by Voriconazole.	Aspergillosis [1F20]	[24]
Posaconazole	DMUL5EW	Major	Decreased metabolism of Vinblastine caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[24]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Vinblastine and Roflumilast.	Asthma [CA23]	[22]
Ofloxacin	DM0VQN3	Minor	Decreased absorption of Vinblastine due to intestinal mucosa variation caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Vinblastine caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[26]
Clarithromycin	DM4M1SG	Major	Decreased clearance of Vinblastine due to the transporter inhibition by Clarithromycin.	Bacterial infection [1A00-1C4Z]	[24]
Trovafloxacin	DM6AN32	Minor	Decreased absorption of Vinblastine due to intestinal mucosa variation caused by Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Sparfloxacin	DMB4HCT	Minor	Decreased absorption of Vinblastine due to intestinal mucosa variation caused by Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Gemifloxacin	DMHT34O	Minor	Decreased absorption of Vinblastine due to intestinal mucosa variation caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Norfloxacin	DMIZ6W2	Minor	Decreased absorption of Vinblastine due to intestinal mucosa variation caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[25]
ABT-492	DMJFD2I	Minor	Decreased absorption of Vinblastine due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[25]
Levofloxacin	DMS60RB	Minor	Decreased absorption of Vinblastine due to intestinal mucosa variation caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Troleandomycin	DMUZNIG	Major	Decreased clearance of Vinblastine due to the transporter inhibition by Troleandomycin.	Bacterial infection [1A00-1C4Z]	[24]
Lomefloxacin	DMVRH9C	Minor	Decreased absorption of Vinblastine due to intestinal mucosa variation caused by Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Telithromycin	DMZ4P3A	Major	Decreased clearance of Vinblastine due to the transporter inhibition by Telithromycin.	Bacterial infection [1A00-1C4Z]	[24]
Erdafitinib	DMI782S	Moderate	Decreased clearance of Vinblastine due to the transporter inhibition by Erdafitinib.	Bladder cancer [2C94]	[27]
Lomustine	DMMWSUL	Minor	Decreased metabolism of Vinblastine caused by Lomustine mediated inhibition of CYP450 enzyme.	Brain cancer [2A00]	[20]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Vinblastine caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[28]
Tucatinib	DMBESUA	Major	Decreased clearance of Vinblastine due to the transporter inhibition by Tucatinib.	Breast cancer [2C60-2C6Y]	[24]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Vinblastine caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[29]
Capecitabine	DMTS85L	Minor	Decreased metabolism of Vinblastine caused by Capecitabine mediated inhibition of CYP450 enzyme.	Colorectal cancer [2B91]	[20]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Vinblastine caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[17]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Vinblastine caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[30]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Vinblastine caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[31]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Vinblastine caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[32]
Nefazodone	DM4ZS8M	Major	Decreased metabolism of Vinblastine caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[24]
Primidone	DM0WX6I	Moderate	Increased metabolism of Vinblastine caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[33]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Vinblastine caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[34]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Vinblastine caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[35]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Vinblastine caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[36]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Vinblastine caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[22]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Vinblastine caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[33]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Vinblastine caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[37]
Itraconazole	DMCR1MV	Major	Decreased clearance of Vinblastine due to the transporter inhibition by Itraconazole.	Fungal infection [1F29-1F2F]	[24]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Vinblastine caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[38]
Ketoconazole	DMPZI3Q	Major	Decreased metabolism of Vinblastine caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[24]
Boceprevir	DMBSHMF	Major	Decreased clearance of Vinblastine due to the transporter inhibition by Boceprevir.	Hepatitis virus infection [1E50-1E51]	[24]
Telaprevir	DMMRV29	Major	Decreased metabolism of Vinblastine caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[24]
Rifampin	DMA8J1G	Moderate	Accelerated clearance of Vinblastine due to the transporter induction by Rifampin.	HIV-infected patients with tuberculosis [1B10-1B14]	[33]
Rifapentine	DMCHV4I	Moderate	Accelerated clearance of Vinblastine due to the transporter induction by Rifapentine.	HIV-infected patients with tuberculosis [1B10-1B14]	[33]
Delavirdine	DM3NF5G	Major	Decreased metabolism of Vinblastine caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[24]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Vinblastine caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[24]
Cobicistat	DM6L4H2	Major	Decreased clearance of Vinblastine due to the transporter inhibition by Cobicistat.	Human immunodeficiency virus disease [1C60-1C62]	[24]
Efavirenz	DMC0GSJ	Moderate	Increased metabolism of Vinblastine caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[39]
Saquinavir	DMG814N	Major	Decreased metabolism of Vinblastine caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[24]
Amprenavir	DMLMXE0	Major	Decreased metabolism of Vinblastine caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[24]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Vinblastine caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[40]
Atazanavir	DMSYRBX	Major	Decreased metabolism of Vinblastine caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[24]
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Vinblastine and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[41]
BMS-201038	DMQTAGO	Moderate	Decreased clearance of Vinblastine due to the transporter inhibition by BMS-201038.	Hyper-lipoproteinaemia [5C80]	[42]
Cinacalcet	DMCX0K3	Moderate	Decreased metabolism of Vinblastine caused by Cinacalcet mediated inhibition of CYP450 enzyme.	Hyper-parathyroidism [5A51]	[17]
Conivaptan	DM1V329	Major	Decreased metabolism of Vinblastine caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[24]
Tolvaptan	DMIWFRL	Moderate	Decreased clearance of Vinblastine due to the transporter inhibition by Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[17]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Vinblastine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[43]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Vinblastine caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[33]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Increased metabolism of Vinblastine caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[22]
Denosumab	DMNI0KO	Moderate	Additive immunosuppressive effects by the combination of Vinblastine and Denosumab.	Low bone mass disorder [FB83]	[44]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Vinblastine caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[45]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Vinblastine caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[46]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Vinblastine and Porfimer Sodium.	Lung cancer [2C25]	[47]
Ceritinib	DMB920Z	Major	Decreased metabolism of Vinblastine caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[24]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Vinblastine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[48]
Osimertinib	DMRJLAT	Moderate	Decreased metabolism of Vinblastine caused by Osimertinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[22]
Capmatinib	DMYCXKL	Moderate	Decreased clearance of Vinblastine due to the transporter inhibition by Capmatinib.	Lung cancer [2C25]	[49]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Vinblastine caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[22]
Idelalisib	DM602WT	Major	Decreased metabolism of Vinblastine caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[24]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Vinblastine caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[50]
Blinatumomab	DMGECIJ	Moderate	Decreased metabolism of Vinblastine caused by Blinatumomab mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[51]
LGX818	DMNQXV8	Moderate	Increased metabolism of Vinblastine caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[52]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Vinblastine caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[22]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of Vinblastine due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[53]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Vinblastine caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[54]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Vinblastine and Thalidomide.	Multiple myeloma [2A83]	[55]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Vinblastine and Tecfidera.	Multiple sclerosis [8A40]	[56]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Vinblastine and Siponimod.	Multiple sclerosis [8A40]	[17]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Vinblastine and Fingolimod.	Multiple sclerosis [8A40]	[57]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Vinblastine and Ocrelizumab.	Multiple sclerosis [8A40]	[58]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Vinblastine and Ozanimod.	Multiple sclerosis [8A40]	[22]
Rifabutin	DM1YBHK	Moderate	Increased metabolism of Vinblastine caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[33]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Vinblastine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[22]
Nilotinib	DM7HXWT	Moderate	Decreased clearance of Vinblastine due to the transporter inhibition by Nilotinib.	Myeloproliferative neoplasm [2A20]	[59]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Vinblastine caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[60]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Vinblastine caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[61]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive myelosuppressive effects by the combination of Vinblastine and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[62]
Modafinil	DMYILBE	Minor	Increased metabolism of Vinblastine caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[18]
Rolapitant	DM8XP26	Moderate	Decreased clearance of Vinblastine due to the transporter inhibition by Rolapitant.	Nausea/vomiting [MD90]	[63]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Vinblastine caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[64]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Vinblastine caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[65]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Vinblastine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[66]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Vinblastine caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[67]
Lonafarnib	DMGM2Z6	Major	Decreased clearance of Vinblastine due to the transporter inhibition by Lonafarnib.	Premature ageing appearance [LD2B]	[24]
Enzalutamide	DMGL19D	Moderate	Accelerated clearance of Vinblastine due to the transporter induction by Enzalutamide.	Prostate cancer [2C82]	[68]
Ustekinumab	DMHTYK3	Moderate	Additive myelosuppressive effects by the combination of Vinblastine and Ustekinumab.	Psoriasis [EA90]	[22]
Tildrakizumab	DMLW9HG	Moderate	Additive immunosuppressive effects by the combination of Vinblastine and Tildrakizumab.	Psoriasis [EA90]	[22]
Risankizumab	DMM32GT	Moderate	Additive immunosuppressive effects by the combination of Vinblastine and Risankizumab.	Psoriasis [EA90]	[22]
Ixekizumab	DMXW92T	Moderate	Additive immunosuppressive effects by the combination of Vinblastine and Ixekizumab.	Psoriasis [EA90]	[22]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Vinblastine and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[69]
Gatifloxacin	DMSL679	Minor	Decreased absorption of Vinblastine due to intestinal mucosa variation caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[25]
Tocilizumab	DM7J6OR	Moderate	Additive myelosuppressive effects by the combination of Vinblastine and Tocilizumab.	Rheumatoid arthritis [FA20]	[22]
Canakinumab	DM8HLO5	Moderate	Additive myelosuppressive effects by the combination of Vinblastine and Canakinumab.	Rheumatoid arthritis [FA20]	[22]
Rilonacept	DMGLUQS	Moderate	Additive myelosuppressive effects by the combination of Vinblastine and Rilonacept.	Rheumatoid arthritis [FA20]	[22]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Vinblastine and Golimumab.	Rheumatoid arthritis [FA20]	[70]
Dexamethasone	DMMWZET	Moderate	Increased metabolism of Vinblastine caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[33]
Sarilumab	DMOGNXY	Moderate	Additive immunosuppressive effects by the combination of Vinblastine and Sarilumab.	Rheumatoid arthritis [FA20]	[22]
Leflunomide	DMR8ONJ	Major	Additive myelosuppressive effects by the combination of Vinblastine and Leflunomide.	Rheumatoid arthritis [FA20]	[41]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Vinblastine when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[71]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Vinblastine caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[22]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Vinblastine caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[22]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Vinblastine due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[72]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Vinblastine caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[22]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Vinblastine and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[69]
Azathioprine	DMMZSXQ	Moderate	Additive myelosuppressive effects by the combination of Vinblastine and Azathioprine.	Transplant rejection [NE84]	[17]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Vinblastine and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[69]
Cinoxacin	DM4EWNS	Minor	Decreased absorption of Vinblastine due to intestinal mucosa variation caused by Cinoxacin.	Urinary tract infection [GC08]	[25]
Nalidixic acid	DMRM0JV	Minor	Decreased absorption of Vinblastine due to intestinal mucosa variation caused by Nalidixic acid.	Urinary tract infection [GC08]	[25]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of Vinblastine and Ganciclovir.	Virus infection [1A24-1D9Z]	[17]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Vinblastine and Valganciclovir.	Virus infection [1A24-1D9Z]	[17]

References

• [1] Vinblastine FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6851).
• [3] BDDCS applied to over 900 drugs
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Effect of the antitumor drug vinblastine on nuclear betaII-tubulin in cultured rat kidney mesangial cells. Invest New Drugs. 2003 Feb;21(1):15-20.
• [6] MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530-9.
• [7] Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin's lymphoma. Int J STD AIDS. 2017 Oct;28(12):1259-1262.
• [8] Development and characterization of a recombinant Madin-Darby canine kidney cell line that expresses rat multidrug resistance-associated protein 1 (rMRP1). AAPS PharmSci. 2004 Mar 9;6(1):E8.
• [9] Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
• [10] Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol Res. 2010 Jan;61(1):76-84.
• [11] Induction of CYP3A4 by vinblastine: role of the nuclear receptor NR1I2. Ann Pharmacother. 2010 Nov;44(11):1709-17.
• [12] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [13] Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
• [14] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [15] Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia. Mol Cancer Ther. 2006 Aug;5(8):1986-94.
• [16] MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005 Sep 20;116(5):824-9. doi: 10.1002/ijc.21013.
• [17] Cerner Multum, Inc. "Australian Product Information.".
• [18] Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
• [19] DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
• [20] Zhou-Pan XR, Seree E, Zhou XJ, et al "Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions." Cancer Res 53 (1993): 5121-6. [PMID: 8221648]
• [21] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [22] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [23] Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
• [24] Antoniou T, Tseng AL "Interactions between antiretrovirals and antineoplastic drug therapy." Clin Pharmacokinet 44 (2005): 111-145. [PMID: 15656694]
• [25] Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
• [26] Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
• [27] Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
• [28] Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [29] Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [30] Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
• [31] Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
• [32] Charasson V, Haaz MC, Robert J "Determination of Drug Interactions Occurring with the Metabolic Pathways of Irinotecan." Drug Metab Dispos 30 (2002): 731-733. [PMID: 12019202]
• [33] Product Information. Marqibo (vinCRIStine liposome). Talon Therapeutics Inc, South San Francisco,, CA.
• [34] Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
• [35] Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
• [36] Bollini P, Riva R, Albani F, Ida et al "Decreased phenytoin level during antineoplastic therapy: a case report." Epilepsia 24 (1983): 75-8. [PMID: 6822234]
• [37] Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
• [38] Product Information. ORAVIG (miconazole). Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.
• [39] Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
• [40] Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
• [41] Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [42] Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
• [43] Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
• [44] Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
• [45] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [46] Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
• [47] Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
• [48] Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [49] Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [50] Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
• [51] Product Information. Blincyto (blinatumomab). Amgen USA, Thousand Oaks, CA.
• [52] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [53] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [54] Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
• [55] Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
• [56] Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
• [57] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [58] Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
• [59] Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [60] Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
• [61] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [62] Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
• [63] Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
• [64] Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
• [65] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
• [66] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [67] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [68] Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
• [69] Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
• [70] Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
• [71] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
• [72] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.